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AN INVESTIGATION OF THE QUANTITY AND TYPE OF FEMALE VETERANS’ 
RESPONSES TO HEPATITIS C TREATMENT SCREENING AND ACCEPTANCE 
 The hepatitis C virus (HCV) is an infection that affects 5 to 25% of veterans, three 
times higher than the general US population. HCV is linked to cirrhosis, liver cancer, and 
death. Women are now the fastest growing group of veterans. Prior studies of HCV 
screening and acceptance among US veterans included mostly males. 
 The purpose of the study was to evaluate whether there were gender differences in 
veterans’ responses to HCV treatment screening and acceptance. 
 This study is a secondary analysis of 4,201 veterans (4,084 male and 117 female) 
from 24 VA Medical Centers between December 1999 and December 2000. The study 
population was older (50.3 years old, + 7.6 years) and racially diverse. Female veterans 
were more educated and less likely to have a history of drug use or incarceration. 
 Female veterans were more likely to meet inclusion criteria compared with male 
veterans (59.0% vs. 49.6%). There was no gender difference in the mean number of 
exclusion criteria met or the proportion of female and male veterans who only had 
modifiable criteria (47.9% vs. 44.9%).  
 Overall, 931 (45.3%) veterans did not accept HCV treatment. There were no 
differences in treatment acceptance between female and male veterans (50.0% vs. 54.9%). 
Reasons for treatment nonacceptance for both female and male veterans were wanting to 
defer treatment (57.1% vs. 59.0%) and concern over side effects (23.8% vs. 10.6%), but 
these reasons were not statistically significant. 
 Female veterans were different socioeconomically and demographically and were 
more likely to meet the HCV treatment criteria. This study’s data, however, suggest that 
the universal, gender-neutral approach to patient screening is as effective with both male 
and female veterans. The high rate of HCV treatment nonacceptance was not statistically 
significant, but concern over side effects was a greater issue for females. Although no 
statistically significant gender biases in HCV screening or treatment acceptance, these 
data suggest that providing different patient counseling, education, and referrals may be 
beneficial. Further study is required to evaluate the overall efficacy of the current 
screening tools. 
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CHAPTER I 
INTRODUCTION 
Statement of the Problem 
The Veterans Health Administration (VHA) is the United States’ largest 
integrated health system (Perlin, Kolodner, & Roswell, 2004).  In 2004, the VHA 
provided medical services to over 4.7 million veterans throughout the nation (Panangula, 
2006). The number of women entering the military is increasing substantially, with 
women now comprising 20% of all new recruits and 15% of those who are serving in 
active duty (Meehan, 2006). Although the number of women veterans is currently 5% of 
the 27 million veterans, the number is expected to be over 10% by 2010 (Meehan, 2006; 
Yano et al., 2006). The VHA has made it a priority to improve women veterans’ health 
care because of the future increase in the number of women veterans. Recent studies 
suggested that access to services for women veterans has improved substantially (Yano, 
Washington, Goldzweig, Caffrey, & Turner, 2003).  Thus, the future increase in the 
population of veterans, coupled with the increased number of women veterans accessing 
veterans’ health care, raises a number of potential environmental- and behavioral-care 
issues, including the use of standardized health-care screening (Meehan, 2006).  
 Health-care programs, including screening and services in the United States, 
traditionally have been built on the principle of evidence-based medicine (Hope, 1995). 
Thus, policies and decisions about screening for diseases or treatments are based upon 
proven, effective medical treatments and interventions that meet the ideals of beneficence 
and reduction of risk to patients. This form of health care would seem to improve the 
health of all people, including women, but there may be some issues with this model of 
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health-care screening and delivery (Rogers, 2004). The first issue is that current medical 
models are based on clinical research. If there are any past biases or gaps in the existing 
research and research literature regarding gender, then the evidence used to develop best 
practices and screening models also would be biased. The second element of bias with 
evidence-based models is the lack of research and evidence about the effectiveness of the 
screenings or interventions for women. This bias may result in the existing screening or 
health-care models being withheld because of a lack of evidence of whether it is effective 
for females, conversely, the screening or treatment may be implemented equally among 
males and females, which may result in inappropriate treatment (Rogers, 2004). One 
example of the use of gender-equal treatment that may not be appropriate is in the 
treatment of cardiovascular diseases. Gender differences in treatment have been well-
researched, and some of the potential factors cited for this continued difference in care 
have been the lack of research regarding the treatment’s efficacy among women (Chang, 
2007). 
    The need to address gender and its effects on good health care of veterans also has 
been the subject of a number of congressional debates and hearings since 1982. At that 
time, the General Accounting Office (GAO) criticized the Veterans Administration (VA) 
for the lack of gender-specific services and again in 1992 (U.S. Government Accounting 
Office, 1982, 1992). Subsequently, legislation was passed earmarking funds to enhance 
women’s healthcare, and this legislated funding has evolved into numerous 
comprehensive women’s health centers through the VHA. In 2001, a national evaluation 
of women’s health programs was commissioned, which showed that there were some 
improvements in women’s health services but that gaps in service still exist for women 
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and that there still exists wide variations in guidelines and care services for women in the 
VHA (Yano et al., 2003).   
 Historically, with women comprising such a small percentage of veterans 
accessing health care, it is understandable that it was difficult to ensure gender-specific 
quality care within the VHA, including health-care screening. Gender-specific care has 
been further compounded by the fact that most health-care providers within the VHA 
have less interaction and experience providing care for female veterans as a result of their 
low prevalence in the health system (Yano et al., 2006). As such, with a traditionally 
male-dominated patient population, the effectiveness of universal (standardized 
regardless of gender, race, or other factors) health-care screening for chronic diseases for 
women has not been examined fully. Similarly, gender differences in treatment 
acceptance have not been explored for patients with the hepatitis C virus (HCV), 
although data suggest that there may be gender differences from other treatment 
modalities such as smoking cessation (Sherman, 2005). 
Research also suggests that women veterans have greater physical and mental-
health burdens relative to female nonveterans (Frayne et al., 2006) and equal or greater 
burdens than male veterans. These data suggest that female veterans thus may have a 
greater need for VA health-care services than their male counterparts, which would 
further support the need to address whether the current VA health-care services are 
appropriate in targeting the female veteran population. 
Even though  the VA has acknowledged the need to further address female 
veterans’ health care through legislation and enhanced programming, there is very limited 
research or data available on women veterans and, in particular, research on women and 
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infectious diseases such as the HCV. In fact, a recent systematic review of 182 women 
veterans’ studies found that most of the research on women veterans was descriptive in 
nature and related to psychiatric conditions such as sexual harassment or health-care 
utilization. This review concluded that experimental studies and studies assessing the 
quality of care for women were rare (Goldzweig, 2006). The lack of women veteran’s 
research needs to be addressed, particularly for diseases that are more prevalent in 
veterans than nonveterans, such as the HCV. 
Data suggest that HCV is three to five times more prevalent among veterans 
(Dominitz et al., 2005) than in the general U.S. population (Armstrong et al., 2006). HCV 
is a blood-borne disease, and so the higher prevalence for veterans may be a result of the 
higher prevalence of risk factors for HCV, including injection drug use and blood 
exposures while in combat (Fireman, Indest, Blackwell, Whitehead, & Hauser, 2005). 
Chronic HCV clearly is linked to the development of cirrhosis, hepatocellular carcinoma 
(HCC), and end-stage liver disease requiring liver transplantation.  These medical 
consequences of HCV infection constitute a significant human and financial burden. 
According to the United Network for Organ Sharing (UNOS), estimated charges per 
person for liver transplantation are $314,600 and an additional $21,900 annually 
thereafter (UNOS, 2008). A recent projection of total HCV-related deaths in the United 
States in the period of 2005 to 2025 is estimated to be 196,000 (95% CI= 178,000 - 
214,000) with present treatment (Deuffic-Burban, Poynard, Sulkowski, & Wong, 2007). 
Thus, the financial and human burden is high for the general U.S. population with respect 
to the hepatitis C virus. It is an even greater burden for U.S. veterans; however, with 
several studies estimating the prevalence in veterans to be at least three-fold higher, at 5 
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to 10% of veterans who access VHA services (Dominitz et al., 2005; Yee, Currie, 
Darling, & Wright, 2006). Unlike other hepatitis viruses, approximately 85% of persons 
who acquire HCV do not clear the virus without treatment. These persons are defined as 
having chronic HCV. The treatment of chronic HCV is aimed at reducing these health 
burdens by slowing disease progression, preventing complications of cirrhosis, reducing 
the risk of hepatocellular carcinoma, and treating extrahepatic complications of the virus 
(Yee et al., 2006). 
Several studies have investigated HCV screening, treatment candidacy, and 
patient acceptance among veterans in the United States. These studies, however, included 
mostly male veterans. In those studies where females were included, the number of 
female veterans comprised less than 5% of participants. Even in a recent, large 
epidemiological HCV veterans study by Dominitz et al. (2005), only 51 of the 1,288 
persons were women. The area of HCV disease needs further exploration, given the 
increasing number of women who are enrolling in the United States military service and 
the increasing number of women accessing health-care services within the VHA for their 
HCV management and care. In particular, it is important to investigate the current 
gender-neutral screening used to evaluate a veteran’s candidacy for HCV treatment and 
to ascertain whether there are gender-different responses to the exclusion criteria. If there 
are differences in the responses to the exclusion criteria in men and women, this might 
indicate potential barriers to treatment candidacy for female veterans. There a need to 
investigate not only whether there are gender differences in responses to the criteria for 
treatment candidacy but also whether there are gender differences in those who are 
offered HCV treatment in their acceptance of treatment. The need for this HCV research 
 6
is even more paramount given the projected increase in deaths of all patients, including 
women, who are not screened adequately and treated for their HCV. 
Purpose of the Study 
The purposes of this study were to evaluate whether there were gender differences 
in veterans’ responses to the screening for HCV antiviral treatment and gender 
differences in those who accept HCV antiviral treatment. HCV antiviral treatment 
screening and HCV treatment acceptance are two separate decision points in the 
treatment process for all veterans being considered for HCV treatment. 
Specifically, to carry out this research, this study examined the quantity (total 
number) of yes responses to the 13 exclusion criteria that comprise the VA’s universal 
screening criteria for HCV (Appendix A). To further investigate the type of responses 
each of the 13 exclusion criteria were examined. As well, the type of responses were 
assessed based on whether the criteria were modifiable (changeable by the patient 
individually or through medical or other supports) or nonmodifiable (permanent or 
unable to be changed regardless of intervention). Identifying whether there are gender 
differences in the responses to modifiable or nonmodifiable criteria is important to assess, 
because HCV treatment screening considers all of the 13 exclusion criteria in the same 
way. Any single positive response excludes a person from HCV treatment. If there are 
gender differences in the responses to the modifiable factors, it may indicate an 
opportunity to address or change these factors and potentially increase the number of 
persons eligible for HCV antiviral treatment.  
Another purpose of the study was to examine whether there are gender differences 
in treatment acceptance of veterans who are offered HCV antiviral treatment. 
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Specifically, the study compared whether there are gender differences in responses to 
HCV treatment acceptance (the number of yes responses to acceptance of HCV 
treatment, Appendix B, question 4). As mentioned previously, regardless of gender, if a 
patient does not meet any of the 13 exclusion criteria for treatment, he or she is offered 
HCV antiviral treatment. HCV antiviral treatment acceptance by patients is not 100%. 
Unknown is whether there are gender differences in HCV antiviral treatment acceptance 
between men and women veterans. This lack of knowledge about gender differences may 
be an issue in HCV positive women because other gender-neutral treatments offered to 
veteran women, such as smoking cessation, have shown differences in treatment 
acceptance (Sherman, 2005).  
Furthermore, in those veterans who do not accept HCV treatment, this study 
examined whether there were gender differences in the reasons why veterans chose not to 
accept HCV treatment, based on six of the seven potential responses to the question that 
asks to clarify the reason why they did not accept treatment (Appendix B, question 
number 5). The seventh response, which is not included in this analysis, has been 
excluded because it relates to patient consent in the study and not to the question of 
treatment acceptance.  
This study will enhance the field’s understanding of whether there are gender 
differences in the responses to treatment eligibility and treatment acceptance of female 
veterans with HCV. This information is important because not only of the longterm 
health consequences of not treating HCV but also this area has limited data and few 
empirical studies. 
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Background and Rationale for the Study 
The number of female U.S. veterans is projected to double by 2010 (Yano et al., 
2006). This changing gender composition of veterans results in different pressures and 
challenges on the Veterans Health Administration (VHA) not only in the provision of 
women’s health services but also in ensuring that the screening of health services is 
appropriate for both genders. Because the VHA’s health system has been built upon a 
biomedical model that focuses on disease and was developed on the principles of gender 
neutrality, the issue of whether veterans’ health services are appropriate for women 
becomes a greater issue. Because there are gender differences in risk factors, age, and 
other factors between male and female veterans, one would hypothesize that there might 
be gender differences in responses to the HCV screening and treatment acceptance; 
however, no research has been conducted to examine whether gender-specific screening 
and treatment acceptance is needed for HCV (Bini et al., 2005). This study examined this 
important health-care issue. 
HCV is not a rare chronic infection. In fact, it affects nearly three million 
Americans (1.8% of the entire U.S. population) and is the leading cause of liver 
transplantation and hepatocellular carcinoma (HCC) in the US (Armstrong et al., 2006). 
Prevalence studies of veterans accessing VHA suggest that the prevalence is much 
greater than in the general population, from 5 to 25% (Dominitz et al., 2005). These data 
suggest that it is an even bigger health issue for the veteran population given the 
significantly higher number of HCV-infected veterans. 
HCV is primarily a blood-borne virus, which means that it is transmitted from one 
person’s blood to another. As such, high-risk behaviors include persons who had received 
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a blood transfusion before 1992 (that is when the blood banks and blood supply began to 
screen for the hepatitis C virus) or have a history of or current injection drug use (IDU). 
Other potential routes of transmission include tattooing, history of multiple sex partners, 
and occupational exposures such as percutaneous or mucosal. In fact, IDU is now the 
primary and most efficient route of infection for the hepatitis C virus (HCV). Recent 
National Health and Nutrition Examination Survey (NHANES) data suggest that at least 
48.4% of all persons with HCV antibodies have a history of IDU (Armstrong et al., 
2006).  
 The natural history of HCV is highly variable, with approximately 15 to 20% of 
all persons who are infected with the HCV able to clear the virus without treatment. The 
other 85% who do not clear the virus are considered to have chronic hepatitis C, and 
these are the persons who are at risk of developing complications related to the infection. 
Of the persons who develop chronic hepatitis C, approximately 15% of them eventually 
will develop cirrhosis (Strader, Wright, Thomas, & Seeff, 2004), and up to 5% of all 
persons with chronic hepatitis C may die as a result of it. HCV is now the primary cause 
of advanced liver disease and hepatocellular carcinoma (HCC) in the United States, as 
well as the leading indication for liver transplantation (Spaulding et al., 2006; Strader et 
al., 2004).  
Dominitz et al. (2005) conducted a prevalence study from 20 randomly selected 
VA medical centers, which comprised 3,184,687 veterans seen at these facilities during 
the period of 1998 to 2000. Using a randomized number generator, 200 veterans were 
selected from each of the 20 facilities for a total sample of 4,000. All patients were 
approached, consented, and asked to complete a self-administered risk questionnaire and 
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had their blood drawn to ascertain their HCV status. Dominitz et al. employed two 
separate techniques to account for nonparticipation: the first involved multiple 
imputations to develop a multiple regression model to predict probability of participation 
and the second methodology used nonparticipation weighting. Of the available 4,000 
potential participants, 1,288 blood results and data were collected for the purposes of this 
study. In this study, 52 of the 1,288 (4.03%, 95% CI = 2.6 to 5.5%) tested positive for 
HCV. Regardless of the correction method used for nonparticipation, the prevalence 
estimate increased to 5.4% (95% CI = 3.3 to 7.5%). This study’s data also suggested that 
prevalence was higher among males (5.6 vs. 1.2); however, the difference in prevalence 
between males and females was not statistically significant, perhaps as a result of the 
small sample size of women (n = 51). The data also showed that prevalence was 
statistically significantly higher among Vietnam era veterans when compared with all 
other service periods (11.0% vs. 2.2%).  
Another important component of this study was its examination of HCV in 
relation to other clinical diagnoses. The examination of other clinical factors is 
particularly important given the universal factors used for screening for HCV antiviral 
treatment and part of the current study’s investigation. Persons with HCV were 
statistically significantly more likely to have a history of, or current, alcohol abuse (15.1 
vs. 3.7), mental illness (11.4 vs. 3.2), or substance use disorder, excluding alcohol (22.6 
vs. 3.9). These three factors, alcohol abuse, mental illness, and other substance use 
disorders excluding alcohol, are all modifiable factors. Although this study was one of 
the largest HCV prevalence studies of veterans undertaken and validated prior studies 
suggesting that the HCV prevalence of veterans is higher than the general U.S. 
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population, there are a number of limitations to this study. One limitation is the large 
number of veterans who chose not to participate (over 68% of the potential sample) and 
thus did not provide a blood specimen for the study. Another issue is that this study was a 
predominantly male population, which also might suggest that risks and behaviors and 
even overall HCV prevalence figures may not be generalizable to female veterans. 
Since 2000, the treatment for HCV has evolved such that two drugs, pegylated 
interferon and ribavirin, taken in combination, are now the standard of care, leading to 
viral clearance in approximately 40% of those with genotype 1 infection, the predominant 
genotype in the US. There are controversies concerning those who are appropriate 
candidates for therapy and whether therapy improves survival. Part of the controversy 
stems from the indolent nature of HCV infection such that many with HCV will die with 
HCV rather than from complications of disease associated with persistent HCV infection. 
Nevertheless, a recent National Institutes of Health (NIH) Consensus Development 
conference clearly recommended screening for HCV infection in high-risk individuals 
and treatment of those with “significant” HCV-associated liver disease (NIH, 2002), 
generally defined as those patients with at least an inflammation of their liver resulting 
from the hepatitis C virus. 
In contrast, recent guidelines by the U.S. Preventive Services Task Force 
(USPSTF) advised against testing for HCV infection in those with risk factors (USPSTF, 
2004). Although the Task Force recognized that complications of chronic HCV infection 
are rising and represent an important public-health burden in coming decades and that 
antiviral therapy can eradicate infection, the Task Force found insufficient evidence to 
recommend for, or against, routine screening for HCV infection in asymptomatic adults 
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at risk. Part of the reluctance to identify those with HCV infection comes from the lack of 
data regarding the benefits of antiviral therapy in preventing long–term complications of 
HCV disease. This lack of data is further compounded by the fact that the majority of 
those with HCV infection are entering the fifth decade of life. As such, they may be at 
greater risk of developing life-threatening nonhepatic comorbidities than of dying from 
complications of HCV disease. Even though there is debate in the general public about 
health screening, the VHA, with a higher prevalence of HCV, has adopted a universal 
screening for HCV treatment (Yee et al., 2006).  
Universal screening of veterans for HCV treatment has not been static. Because 
these guidelines are based on a biomedical model that includes both clinical study data 
and best practices, there have been changes or modifications to the universal screening 
prior to the existing screening guidelines. For example, patients with ongoing injection 
drug use were previously excluded or “screened out” of HCV treatment until 2002 (Bini 
et al., 2005; Dalgard et al., 2002; NIH, 2002). Injection drug users were excluded because 
there was a concern about the potential for HCV reinfection as well as the concern for 
treatment adherence (Currie et al., 2008). In 2002, however, the NIH Consensus 
Statement changed the screening criteria, allowing for all patients with chronic HCV 
infection to be considered for HCV antiviral therapy (NIH, 2002; Yee et al., 2006). Even 
though the HCV treatment criteria have broadened, there is still limited access to HCV 
treatment for IDU patients. This limited access to treatment can be attributed to a number 
of modifiable factors, including concern for ongoing drug use and its impact on treatment 
adherence and the potential for lower responses to HCV therapy, but also, for those who 
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are treated successfully, the concern for potential reinfection (Dalgard et al., 2002, 
Spaulding et al., 2006).  
Sociodemographic and epidemiological studies have shown that persons with 
chronic hepatitis have a high prevalence of current or past medical, psychiatric, and 
substance-use disorders (Lehman & Cheung, 2002). These factors are important for a 
number of reasons. First, HCV and related liver-disease progression can affect negatively 
mental health, quality of life, and other medical symptoms (Yee et al., 2006). Second, the 
higher prevalence of nonmodifiable factors such as medical and modifiable factors such 
as psychiatric, and substance-use comorbidities can exclude persons from HCV antiviral 
treatment if not controlled. Third, these symptoms actually can worsen as a result of the 
HCV treatment, which can lead to reduced compliance and reduce positive treatment 
outcomes to HCV treatment.  
Chronic hepatitis C is a disease that, if untreated, can lead to scarring of the liver 
(cirrhosis), hepatocellular carcinoma (liver cancer), or even death. The primary means of 
managing veterans with HCV disease is through HCV antiviral therapy. The success of 
antiviral therapy is dependent on the patient’s ability to take the medication as directed 
and to be knowledgeable about managing the treatment’s side effects that otherwise could 
lead to noncompliance, dose reduction, and treatment discontinuation (Yee et al., 2006). 
 In an effort to maximize HCV treatment success, the VHA has developed 
standardized screening criteria to assist medical providers with the management and 
education of veterans with chronic hepatitis C (see Appendix A). This standardized 
screening includes 13 criteria. These 13 are considered exclusion criteria because a 
patient will be excluded from treatment if he or she has a positive (yes) response to any 
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one of the criteria. It is this standardized screening that not only forms the basis of HCV 
treatment eligibility but also the type of patient education and counseling patients receive.  
The standardized criteria, like many VHA health-screening tools, were developed within 
a traditionally homogeneous male patient population (Goldzweig, 2006). Until recently, 
with a small female veteran population, the use of this VHA screening tool did not appear 
to be problematic; however, with the increasing number of women veterans accessing 
VHA services for all health services, including HCV, there is little known whether 
existing health-screening tools are appropriate for both male and female veterans. 
The second key decision point after the universal screening for HCV treatment 
eligibility is when veterans who are eligible for HCV treatment are offered treatment. The 
offering of HCV treatment is not gender-specific; however, it might be influenced by 
concerns of side effects, ability to comply and other medical and nonmedical issues (Yee 
et al., 2006). It is not known whether there are gender differences in HCV treatment 
acceptance or if there are gender differences in the reasons for nonacceptance of HCV 
treatment. The examination of gender differences in acceptance of treatment, again, is 
important, because if there are gender differences in acceptance of antiviral treatment, 
then the way that providers educate and counsel patients during their discussions about 
HCV treatment may need to be changed. 
Theoretical Rationale 
The theoretical rationale that has contributed to the current standardized patient 
screening and subsequent treatment acceptance for chronic hepatitis C is the biomedical 
model. The biomedical model is built upon the principle of identifying the soma or 
symptom of a disease or medical problem independent of the social, psychological, or 
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human context of the issue (Alonso, 2004). Advocates of the biomedical model suggest 
that it insures that the physician obtains information from the patient that is neutral to 
gender, race, and social circumstances and is relevant only to the disease and diagnosis. 
On the surface, this gender-neutral approach appears appropriate; however, there may be 
several flaws with this approach for many diseases, including HCV. First, this model 
cannot take into account actual physiological, social, behavioral, or other gender-related 
differences. This means that contextualizing screening responses or integrating other 
factors in health-care screening is excluded. Second, the biomedical model is developed 
based on clinical evidence, which, historically, has been conducted in a homogeneous, 
predominantly male population. If health-care screening and decisions are being made 
based upon clinical trials and evidence from a male-oriented, homogeneous population, it 
is unclear if these data would be generalizable to females or other diverse population 
groups (such as persons from different races, ethnic backgrounds, and ages). It is these 
two factors that may bring in to question the appropriateness of the biomedical model. 
The biomedical model formed the basis of universal-health screening forms to 
assess for disease well into the 1970s (Engel, 1979). The principles of this model are the 
foundation of Western Medicine, which eschews two dominant ideas: dualism and 
reductionism (Rasmussen, 1975). Dualism can be defined as a means for the physician to 
separate the mind from the body and the behavior of the disease from the person’s 
behavior or other social or psychological components. The second parameter of this 
model is reductionism. In science or medicine, this principle takes a complex organism 
such as a human being and builds upon the idea that it can best be understood by focusing 
on discrete parts of the whole rather than as a complete entity. For example, hepatitis C is 
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a virus that affects the liver, and so, to address this disease, one would focus attention 
specifically on this area of the body, and all screening questions and clinical tests would 
be related directly to this part of the organism. This type of reductionism looks at cause 
and effect and may incorporate the ideas of clinical research and evidence-based 
medicine to confirm its validity (Engel, 1977).  
The reductionist model is the basis of screening for disease detection, including 
hepatitis C. In using the biomedical model’s reductionism in screening, all of the 
responses to the universal screening for hepatitis C are viewed as a discrete yes-or-no 
binary response to screening questions in order to ascertain the information and assess a 
person’s eligibility or appropriateness for treatment. Using this model, the hepatitis 
screening form uses a number of clinical laboratory tests, including liver function tests, 
liver biopsy data, and blood-cell counts to determine the probability of the patient with 
hepatitis C being a good candidate for HCV treatment (Yee et al., 2006).  
In the late 1970s, Engel (1979), a physician, challenged this traditional biomedical 
model and advocated for a biopsycho-social model of medicine that would integrate 
psychological and social factors with the existing biomedical model. The biopsycho-
social model argued that this integration would provide a better context and a more 
holistic means of assessing patients and patient health (Engel, 1979). This model attempts 
to integrate a more holistic approach to medicine and medical screening and to replace 
the idea of dualism and reductionism with a more systems-wide approach to medicine, 
including screening and assessment (Engel, 1979). As such, the screening for diseases 
and treatment eligibility has expanded to incorporate mental health, behavioral, and other 
nonbiomedical questions (see screening form, Appendix A). The possible advantages to 
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this approach are that the physician, health-care provider or health-educator, can use this 
approach to identify not only the biomedical criteria but also risks and behaviors that 
might affect outcomes.  
The current hepatitis C treatment screening exclusion-criteria form screens for 
both biomedical and nonbiomedical criteria. For the purposes of this study, biomedical 
criteria are considered nonmodifiable criteria or criteria that cannot be easily changed or 
modified. The nonbiomedical criteria are the criteria that may be changed through 
treatment or changes in behaviors (see Definitions of Terms). The hepatitis C- screening 
exclusion-criteria form includes 13 criteria in which 4 of the criteria are nonbiomedical, 
ongoing or recent substance use, preexisting psychiatric conditions (including 
depression), inability to remain compliant, and pregnancy (see screening form, Appendix 
A, and Table 1 in Chapter III for more details). The issue is, however, that the method of 
HCV screening still treats all of the factors as biomedical and in a reductionist way (as a 
yes-or-no response to any of the exclusion criteria). Also, rather than taking a holistic 
approach to these criteria, a patient must meet none of the exclusion criteria to be eligible 
for treatment, regardless of the number (quantity) or type (modifiable or unchangeable) 
of the patient’s responses, which suggests that this type of screening adheres to the 
traditional biomedical model. 
The biomedical model also provides the theoretical foundation for the approach to 
patients (regardless of their gender) who are eligible to treatment and who are offered 
treatment. The biomedical model is based on evidence-based medicine, most of which 
have been developed using a male population (Rogers, 2004). If the evidence that forms 
the basis of medical screening and decisions is built upon data or evidence from clinical 
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trials that were primarily male and homogenous, it is not certain if the evidence is, in fact, 
generalizable to females or other populations. This theoretical approach is important in 
understanding how the health education and counseling that is provided to patients with 
hepatitis C who are eligible for HCV antiviral treatment addresses the patient equally, 
regardless of gender. This model also does not allow for variations in the process to 
address any additional factors specific to women or even historic differences in 
acceptance. 
 In summary, the biomedical model’s dualism and reductionist approach underlies 
the management approaches to most chronic medical conditions, including the current 
standardized screening for hepatitis C. This model also is the foundation for the method 
of offering treatment to those patients who are eligible for hepatitis C treatment because it 
is objective and is not varied in approach as a result of gender or other social, 
environmental, or other nonbiomedical factors. The HCV screening and subsequent 
counseling and patient education within this approach have been based on male-
dominated clinical trials and clinical-research experience. This theoretical rationale, 
however, does not recognize that there may be biological and other differences between 
males and females. The current study examines whether there are such gender differences 
to provide better understanding whether the biomedical-based theoretical rationale for 
HCV treatment candidacy and education is appropriate for male and female veterans. 
Research Questions 
The following research questions will be investigated: 
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1. To what extent are there gender differences in the quantity and type (whether 
they are modifiable or not) of responses to standardized patient screening in veterans with 
chronic HCV?  
2. If there are gender differences in the type of responses to standardized patient 
screening, is this difference associated with risk factors, such as alcohol use, 
socioeconomic differences, such as level of education, and demographic factors, such as 
race or ethnicity, of veterans with chronic HCV? 
3. To what extent are there gender differences in treatment acceptance in veterans 
who are offered HCV antiviral treatment? 
 4. For those who do not accept HCV treatment, to what extent do the reasons for 
nonacceptance differ by gender? 
Significance of the Study 
This study may have an educational impact not only on the way that veterans with 
hepatitis C are screened for HCV antiviral treatment but also on the way that physicians, 
nurses, and other health-care providers offer and educate patients who are eligible for 
HCV antiviral treatment. The results of this study may provide a better understanding of 
whether there are differences between male and female veterans to the standardized 
screening for HCV treatment. These data are important to ascertain in order to assess 
whether the current screening is appropriate and relevant to both men and women. The 
outcomes from the current screening are the foundation of patient education, patient 
counseling, and the offering of treatment for any patients infected with hepatitis C, 
regardless of gender. If this study identifies differences in gender, then the postscreening 
education and counseling process may be affected. A second significant element of this 
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study is the examination of whether there are gender differences in acceptance of 
treatment. This examination of gender differences in acceptance of treatment, again, is 
important, because if there are gender differences in acceptance of antiviral treatment, 
then the way that providers educate and counsel patients during their discussions about 
HCV treatment may need to be changed.  
Furthermore, by having a better understanding of gender differences in veterans 
with hepatitis C who are being screened and cared for, the VA healthcare system may be 
able to use these data to modify or further examine patient screening and education for 
other chronic diseases such as HIV.  Another potential finding of this study is the absence 
of gender differences in responses to the current standardized HCV treatment screening 
and subsequent HCV treatment acceptance. This finding also will be important because it 
will provide additional support to continuing the existing standardized screening, patient 
education, and counseling that currently is available within the VHA system.  
Overall, this study is significant because it will expand the field of knowledge 
regarding HCV management and care of female veterans, a group that has been 
understudied and underrepresented due to the historically small numbers of female 
veteran patients. The need to examine the current HCV treatment screening and treatment 
acceptance for both male and female veterans is an increasingly important research area 
for a number of reasons. First, it can impact the increasing number of the 225,000 
veterans (both male and female) who already have been identified as having hepatitis C 
infection in the VA. Second, because the number of female veterans accessing VHA 
services is expected to almost double from 5.5% in 2000 to 10% by 2010, and the number 
of veterans (both male and female), additional research examining the current HCV 
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treatment screening and patient acceptance of both male and female veterans may affect 
the current quality and standard of care of veterans with hepatitis C. Finally, there are 
more global veterans’ health implications of this study because of the opportunity to 
evaluate the biomedical model’s appropriateness in addressing gender issues. The current 
study may provide additional insight into the need to address and expand the current 
model within the VHA.   
Definition of Terms 
The following are the operational definition of key terms used in this study. There 
may be other definitions for the terms listed below; however, for the purposes of this 
study, the stated definitions apply. 
Biomedical criteria: These are medical criteria that are not changeable or modifiable by 
behavior change or treatment intervention. These are also known as unchangeable factors 
in HCV patients. Nine of the 13 exclusion criteria for HCV screening are considered 
biomedical (Bini et al., 2005).  
Exclusion criteria: These are the 13 items (Appendix A) that are used as part of the 
standardized screening to evaluate veterans eligibility for HCV antiviral treatment. If a 
patient has a positive response to any one of the 13 items, he or she is considered not 
eligible for HCV treatment (Bini et al., 2005) 
Fibrosis: Is an indication of liver disease. There are generally four stages of liver disease 
with stage zero indicating no disease and stage four indicating cirrhosis or scarring of the 
liver. Fibrosis is usually identified through a liver biopsy (Poynard et al., 2003). 
Hepatitis: Means inflammation or irritation of the liver (NIH, 1997; Armstrong et al., 
2006). 
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HCV RNA test: The presence of HCV Ribonucleic acid (RNA) means that there is still 
HCV virus present in the blood. A patient has a laboratory test before being screened for 
HCV treatment to see whether there is virus in their system. If a patient has no detectable 
virus, then it means that he or she has cleared the virus and do not require HCV 
treatment. The HCV RNA test also is done while someone is being treated for their HCV 
and immediately following treatment to assess whether the treatment is being effective or 
not. If they have an HCV RNA test that is undetectable 6 months after completing HCV 
treatment, they are said to have a sustained virological response (SVR) and are cured of 
their HCV (NIH, 2002; Yee, Currie, Darling, & Wright, 2006). 
Hepatitis C virus: There are a number of viruses that can affect the liver, such as hepatitis 
A, hepatitis B, and hepatitis C. The Hepatitis C virus (HCV) is a blood-borne virus, 
which means that it is spread through hepatitis C infected blood-to-blood contact. 
Primary modes of transmission of the HCV virus are through sharing needles and other 
equipment to inject drugs, sharing unsterile tattooing equipment, and, persons who 
received blood transfusions with blood that was infected with hepatitis C (prior to 
screening for this in the blood banks). Approximately 15% of those who are infected with 
the virus are able to clear it without treatment. The other 85% are considered to have 
chronic HCV. Persons with chronic HCV are the individuals who would be screened to 
try and clear or “cure” the virus. There is no vaccine for HCV. As a virus that affects the 
liver, HCV can lead to cirrhosis (scarring of the liver) and even death (NIH, 2002; 
Armstrong et al., 2006). 
HCV Treatment: All patients with chronic HCV infection are potential candidates for 
antiviral therapy. Currently, standard antiviral treatment for chronic HCV involves once 
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weekly pegylated interferon (peginterferon alfa) injections and daily oral ribavirin. The 
duration of HCV treatment varies, but it is usually 6 months or 12 months depending on 
the strain of the HCV virus (genotype) and a number of other factors. The effectiveness 
of the treatment ranges from 30 to 45% in patients with genotype 1 to 90% in those with 
genotypes 2 or 3 (NIH, 2002; Yee, Currie, Darling, & Wright, 2006). 
Modifiable factors in HCV patients: These factors are screening factors used to assess 
patient eligibility for HCV treatment that potentially are modifiable or changeable by the 
patient individually or through medical or other supports. Examples of these types of 
factors are four criteria on the VA universal screening form: ongoing or recent substance 
use, preexisting psychiatric conditions, inability to remain compliant with treatment, and 
patient or partner is pregnant or actively nursing (Bini et al., 2005)  
Nonbiomedical criteria: These are modifiable or changeable criteria that potentially are 
changeable or modifiable by the patient individually or through medical or other 
supports. These are known also as modifiable criteria. Four criteria on the VA universal 
screening form are considered nonbiomedical: ongoing or recent substance use, 
preexisting psychiatric conditions, inability to remain compliant with treatment, and a 
patient or partner who is pregnant or actively nursing (Bini et al., 2005). 
Nonmodifiable factors in HCV patients: Nonmodifiable factors in HCV patients are the 
screening factors used to assess patient eligibility for HCV treatment that would be 
impossible to change or are absolute exclusions for HCV treatment. Examples of these 
types of factors would include 9 of the 13 criteria on the HCV treatment exclusion form 
(see Appendix A) , prior treatment, hypersensitivity to the medications, 
hemoglobinopathies, evidence of advanced liver disease, having hepatitis B, preexisting 
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medical conditions, evidence of ischemia, concurrent use of other investigational 
therapies, and a history of organ transplantation (Bini et al., 2005). 
Quantity of HCV screening responses: A person is excluded from HCV treatment if he or 
she responds yes to just one of the 13 exclusion criteria. As such, a person who had 4 yes 
responses (met four exclusion criteria) is treated no differently than a person who has 
only one exclusion criteria. The quantity of HCV screening responses will be defined as 
the number of persons who responded to yes for one, two, three, and up to 13 potential 
exclusion criteria screening responses, rather than just a single determination of yes or no 
treatment candidacy based on a single yes response (Bini et al., 2005). 
Sustained virological response: A sustained virological response (SVR) is defined as 
someone who has been treated for their chronic HCV and has no presence of virus based 
on laboratory tests 6 months after completion of the HCV treatment. This patient is 
considered “cured” of HCV (NIH, 1997; Yee, Currie, Darling, & Wright, 2006).  
Treatment Acceptance for HCV Treatment: Treatment acceptance for HCV treatment is 
the number of persons who responded yes to the offer of HCV treatment, which is 
question #4 on the Treatment Candidacy and Decision form (see Appendix B). When a 
person did not accept HCV treatment (a no response), he or she was asked the reasons 
why he or she  did not accept treatment, and the potential responses are recorded 
accordingly. These two questions were used in a standardized patient teleform in all study 
patients who did not meet any of the exclusion criteria for HCV treatment (see Appendix 
B) (Bini et al., 2005). 
Type of HCV screening responses: The current HCV treatment screening exclusion 
criteria do not differentiate between the 13 yes-and-no responses. This study evaluated 
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the responses as individual responses and qualified the types of responses into either 
modifiable or nonmodifiable responses. For example, ongoing or recent substance use is 
a modifiable factor that is different than advanced liver disease, which is an unchangeable 
factor (Bini et al., 2005). 
Universal screening for HCV treatment: Universal screening for HCV treatment in the 
VA involves the use of a standardized set of 13 questions that veteran patients are used to 
determine eligibility for HCV antiviral treatment. These questions were used in a 
standardized patient teleform in all patients in the original source of this study (see 
Appendix A) (Bini et al., 2005). 
Summary 
 An overview of the background and need for the study, which included the higher 
prevalence of HCV infection in veterans, as well as the increasing growth in the number 
of female veterans accessing VHA was provided. HCV infection was then discussed in 
the context of the long-term health consequences of patients who are not treated for this 
chronic disease. This overview of HCV infection was followed by a discussion of the use 
of the gender-neutral biomedical model as the rationale for medical screening, including 
the VHA’s universal screening for HCV treatment.  
In this chapter, an overview of recent research and epidemiological data were 
provided. These data highlighted two important points: first, that there may be gender 
differences in screening and in treatment acceptance for other chronic diseases and, 
second, that there was a lack of females (and, in many cases, no female) veterans 
included in the clinical research that provided the foundation for the current HCV 
treatment screening. These two points support the need to examine whether there are 
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gender differences in both screening for HCV treatment, as well as whether there are 
gender differences in acceptance of HCV treatment. Additionally, a definition of terms 
was provided in this chapter to clarify special term used for the purposes of this 
dissertation. 
Chapter II contains a review of the relevant empirical research literature 
pertaining to the independent variable gender and its association with VA health-care and 
treatment services. Chapter III provides a framework of this study’s methodology, 
including an overview of the original study that is the basis of the current study. Chapter 
IV contains the results of this study with respect to the four research questions. Chapter V 
provides a discussion of these data in the context of the limited published data in this 
area, its implications for practice, and for future research. 
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CHAPTER II 
REVIEW OF LITERATURE 
The purposes of this study were to evaluate whether there are gender differences 
in veterans’ responses to screening for HCV antiviral treatment and gender differences in 
the acceptance of HCV antiviral treatment. In reviewing the literature, however, the 
number of empirical studies of women veterans is limited, which may be due to the 
historically low numbers of women veterans or the historical perspective of providing 
gender-neutral services within the military and subsequently to its military veterans. As 
recently as 2004, the bulk of the research on gender and veterans issues has focused on 
sexual harassment and specific women’s health issues rather than on chronic diseases 
(Goldzweig, 2006). 
In this chapter, there is a review of the existing literature available on gender 
differences in veterans accessing the Veterans Health Administration (VHA) services, 
gender differences in other kinds of treatment services, and gender differences in 
treatment acceptance. Additionally, there is a review of empirical research regarding 
hepatitis-C-virus (HCV)-treatment adverse events as well as studies that address liver- 
disease progression between genders. 
Gender Differences in Veterans Accessing VHA Services  
 There are differences in patient characteristics between male and female veterans 
accessing VHA services, as well as gender differences of their utilization of these 
services. Historical data suggest that women veterans, on average, are younger, more 
educated, and less likely to have served in an active combat zone (Skinner, 2002). These 
are all factors that one might consider positive from a health perspective. Contrarily, 
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other data suggest that women are more likely to have a history of sexual trauma and self-
reported mental-health issues (Frayne et al., 2006). Results of research also suggest that 
women veterans have less social-support than their male counterparts (Frayne et al., 
2007). These are all factors that might affect the response to a universal screening. 
 A large study by Frayne et al. (2006) examined the health status of women 
veterans compared with male veterans using the Large Health Survey of Veteran 
Enrollees database. This data set included 28,048 women and 651,811 men who accessed 
VHA in the years 1996 to 1999. This study used the Veterans Short Form-36 (SF-36) 
instrument and data about veteran’s social support. Frayne et al. used Student’s t tests to 
compare the eight dimensions of the SF-36 across three age groups: less than 45, 45 to 
64, and greater than or equal to 65. The investigators considered a small effect of 20% of 
one SD for the 8 scales of the SF-36 to be clinically significant. In each age stratum (18 
to 44, 45 to 64, and ≥65 years), Physical Component Summary (PCS) and Mental 
Component Summary (MCS) scores were compared using gender as the independent 
variable. They also performed multiple regression analyses on Physical Component and 
Mental Component Summary scores using gender as the independent variable and 
controlling for age, race, and education. The investigators also conducted a Student’s t-
test analysis by gender and age for patients with and without social support.  
The results from the Frayne et al. (2006) study showed that women had less social 
support (defined as married or having someone to take them to the doctor if they were 
unwell) than men across all age groups. For example, in veterans over 75 years of age, 
over 15.1% of women had no one to take them to the doctor compared with 9.6% of the 
men.  When mean SF-36 summary scores for physical- and mental-health status of 
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women versus men were compared against the three age groups, women had statistically 
significantly higher values than men on all components, with the exception of the 18 to 
44 age group, where women had lower values on the MCS (42.8 vs. 43.4).  
This study also compared SF-36 scores from this veterans’ cohort with women 
seeking care in the private sector from the Medical Outcomes study (mean age was 52 for 
the veteran women vs. 46 for the nonveteran women). Women veterans consistently had 
lower values, on average, on all domains, in particular, Bodily Pain (49.1 vs. 65.1), Role 
Emotional (60.6 vs. 76.2), and Social Function (59.8 vs. 80.0). The reported poorer 
overall health of female veterans compared with females in the general population 
suggests that female veterans may not be different than male veterans, but they may be 
different than their nonveteran female counterparts, which further supports the need for 
an investigation into this group of women with reported poorer overall health than 
women in the general U.S. population. The strength of this study is that it is a large study 
of male and female veterans, but there may be some response bias between those who 
responded to this survey and those who did not. For example, the persons who responded 
might be more or less healthy than those who did not. Another potential bias is the use of 
the SF-36 in a veterans’ population. There is the potential for construct validity issues of 
such an instrument, similar to what the current study is examining with the HCV 
screening form. Another limitation of the study is the definition of social support, which 
was defined by having someone able to take them to the doctor if they were unwell. This 
definition is very narrow and may exclude persons, for example, with social supports 
who have transportation or mobility issues. 
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 Another cross-sectional study by Frayne et al. (2007) investigated whether there 
were any gender differences in outpatient and inpatient use and costs of care of veterans 
accessing VHA services. It was a large study of all veterans who had utilized VHA 
services in 2002 with confirmed gender data, and it had a total study population of 
4,122,381 (178,849 women). The independent variable for this study was gender and the 
dependent variables were VHA services utilization and VHA service costs. Other 
variables that were controlled were age and psychiatric conditions. Chi-square analyses 
were performed to compare sociodemographic and other medical conditions. Means were 
compared by gender on inpatient and outpatient utilization. Overall, female veterans were 
younger with a mean age of 50.1 (SD=17.0) compared with men (63.6, SD=13.9). The 
unadjusted differences comparing outpatient utilization and inpatient days suggested that 
female veterans compared with male veterans had statistically significant more outpatient 
utilization (11.8%) and less inpatient days (25.9%). A log-linear analysis was performed 
on these results, controlling for age and medical conditions. The results of this study 
suggest that there were statistically significant differences in women’s usage of 
outpatient-care days (1.3%) and less inpatient-care days (10.9%) after adjusting for age 
and medical conditions (including mental health). The limitations of this study are that 
Frayne et al. (2007) did not account for female or male veterans’ utilization of non-VHA 
services. The strengths of this study are its large size and comprehensive single VHA 
database that records all medical data for all veterans accessing VHA. These data suggest 
that there are gender differences in accessing VHA health-care services, which supports 
the need to assess where there are gender differences in treatment acceptance for HCV 
treatment, which is an outpatient service. 
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 There has been empirical research that suggests that there are differences in 
treatment and treatment services for male and female veterans (Hoff & Rosenheck, 1998; 
Stecker, Han, Curran, & Booth, 2007). These study data support this study’s examination 
of gender differences for persons with chronic hepatitis C. The study by Sherman et al. 
(2005) examined gender differences in smoking-cessation services. The VHA has 
implemented universal-screening guidelines to ascertain treatment eligibility and 
treatment initiation for smoking-cessation services (Sherman et al., 2005).  These 
universal guidelines are similar to the universal treatment screening for HCV in the fact 
that they are used for all veterans being screened for that chronic disease regardless of 
their gender. The Sherman study involved a random sample of 26,966 eligible patients, of 
whom 10,567 consented to participate in the study (comprising a 44% refusal rate). Of 
those veterans who agreed and participated in baseline surveys, 1,941 were defined by 
the screening criteria as smokers and were part of the 12-month followup. Followup data 
were collected on 1,150 (59.2%) of the baseline smokers (129 women and 1,812 men) 
from 18 VA medical facilities to assess smoking-cessation services received by this 
group. The researchers conducted chi-square tests to compare discrete variables and 
analyses of variance (ANOVA) for continuous variables for the 1,150 veterans who had 
provided baseline and followup data. Logistic regression was used to evaluate factors 
associated with receipt of smoking-cessation treatment services. Baseline demographics 
showed that women were statistically significantly younger than men (50 vs. 58) and 
were statistically significantly more likely to have a college education (80 vs. 54%). At 
baseline, the rates of education and counseling for smoking cessation were the same for 
women and men, but the rates of prescription treatment, using the universal screening, 
 32
was much lower among women than among men (16 vs. 25%, Odds Ratio (OR)=.5, 95% 
CI=.3-.9). Twelve-month followup of these persons at baseline showed similar results. 
Multivariate analysis showed that gender (OR=.5, 95% CI=.3-.9), better self-perceived 
health (OR=1.5, 95% CI=1.1-2.0), and chronic obstructive pulmonary disease (COPD) 
(OR=1.6, 95% CI=1.2-2.0) were independently associated with prescription nicotine 
treatment.  
There are a number of limitations of this study including the large number of 
persons who did not participate in the study. This large number of nonparticipants may 
suggest a skewed sample of either healthier individuals or persons who were not 
interested in obtaining universal screening for smoking cessation. Also, the attrition rate 
of the sample in one year was just over 40%. The high attrition rate in the study also may 
skew the results to the study participants who are healthier or more able to adhere to 
study and smoking treatment protocols of the study. Finally, the number of women, 
similar to many VA studies, was low relative to the number of men. Even though there 
are these limitations, the results of this study suggest that there are gender differences to 
universal screening for smoking-cessation treatment services in veteran patients.      
The studies in this section suggest that there are gender differences in patient 
characteristics, such as age, mental- and physical-health scores on SF-36, and in 
environmental factors, such as social supports. As well, the studies that were cited in this 
section suggest that there are not only differences between genders for age and medical 
conditions but also differences in health-care utilization between male and female 
veterans in inpatient, outpatient, and specialized outpatient services. The gender 
differences identified in these studies may suggest that there are also gender differences 
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in patient responses to the universal (gender-neutral) screening form for hepatitis 
treatment, thus supporting the current study’s purpose. The studies in this section were 
also limited to other disease modalities and different treatment focus, further supporting 
the need to examine whether the findings of these studies are generalizable to female 
veterans with chronic hepatitis C.  
Female Veterans’ Acceptance of Treatment 
There are many factors associated with whether a person accepts treatment or 
initiates medical treatment. One such factor is self-perceived health. Many studies have 
shown that if a person perceives himself or herself to be unhealthy, then he or she will 
require more supports and are less functional than a person who perceives himself or 
herself as healthy (Idler, 1997). Even with the research contributions examining self-
perceived health, little research has been conducted to assess whether perceived health 
affects health-care utilization and treatment and, in particular, in women. Bosworth, 
Butterfield, Stechuchak, and Bastian (2000) conducted a study of women veterans to 
assess whether self-rated health status was associated with health-service use (treatment) 
in a primary-care clinical setting. In this study, 139 female veterans, with consecutive 
appointments at a single VA medical center completed the Primary Care Evaluation of 
Mental Disorders questionnaire (PRIME-MD). This is a one-page self-administered 
questionnaire consisting of 28 yes-or-no questions about symptoms or signs present 
during the past month. This questionnaire serves as an initial screen for mental disorders 
and has good agreement with independent mental-health providers (κ = .65, overall 
accuracy, 85%, sensitive and specificity .75 and .90, respectively; Spitzer, 1999). Health-
care utilization and treatment data were collected from the VHA’s comprehensive patient 
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record system. The investigators used Cochran-Armitage Trend Tests to examine trends 
between demographics and self-reported symptoms and Kruskal-Wallis tests to examine 
the relationship between self-reported health and actual health-care utilization and 
treatments.  
The Bosworth  (2000) study data showed that fair or poor self-reported health 
when compared with excellent health was related statistically significantly to an 
increased percentage of physical- and mental-health symptoms in all medical symptom 
categories including depressed mood (68.5 vs. 35.7), headaches (71.7 vs. 42.9), and joint 
pain (94.4 vs. 55.6). Logistic regression analysis examined self-rated health with the 
number of outpatient hospital visits over a year and, using a stepwise method, adjusted 
for age, race, and marital status. Women who reported their health as being fair or poor 
when compared with those reporting excellent or very good health were statistically 
significantly 5.2 times more likely to have more than 12 outpatient visits in the previous 
year (5.2, 95% CI = 2.2 – 12.3). Race also was statistically significantly associated with 
healthcare utilization and treatment. European American women were statistically 
significantly 2.4 times more likely to access health-care services than non-European 
American women (2.4, 95% CI = 1.1 – 5.2). These study data suggest that self-reported 
health status is reflective of additional health-care utilization and treatment. Although this 
study was informative, it was at a single VA center and may not be generalizable to the 
general VA female veteran population. These data may provide additional information 
into patient acceptance of HCV treatment because, if this model were applied to the HCV 
patient acceptance, the persons who self-report excellent health and who in essence 
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would be the better candidates for HCV treatment may be less likely to engage or utilize 
health-care compared with persons in poorer health.  
 Another study by Stecker et al. (2007) investigated treatment utilization and 
acceptance of female veterans for intensive outpatient substance-use treatment services. 
The study population was identified as all veterans who had received at least one 
inpatient or outpatient substance-use service in 1999 from the VHA’s national medical 
record database. The investigators obtained a matched no-treatment group of veterans 
who received a substance-use diagnosis but who had not accepted substance-use 
treatment. They had 8,329 total veterans who had received treatment (247 women) and in 
the matched no treatment group, 7,328 (198 women). Age, gender, race, and medical and 
psychiatric cormorbidity data were collected. Chi-square tests of independence for 
categorical variables and two independent-sample t tests were conducted on continuous 
variables. Using treatment as the dependent variable, logistic regression was performed 
on the subset of all women in both treated and untreated groups, using age, marital status, 
race, and diagnostic variables as the explanatory variables.  
Overall, in the Stecker et al. (2007) study, women were statistically significantly 
younger (41.3 vs. 47.1 years) and statistically significantly less likely to be homeless 
(5.4% vs. 9.3%). In the treatment group, only 2.8% were women, even though 31% of 
female veterans reported hazardous or problem drinking. In this study, female veterans do 
not access substance-use treatment services equally as men. Bivariate analyses suggested 
that women veterans were statistically significantly more likely to have anxiety, bipolar, 
depression personality disorders, and Post Traumatic Stress Disorder (PTSD) than men. 
In the subset of women veterans, the results of the logistic regression examining factors 
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associated with substance-use treatment indicated that having major depression 
(OR=3.18) and having bipolar disorder (OR=2.44) were the only diagnostic variables 
associated with treatment participation. One of the limitations of this study is the fact that 
female veterans may access substance-use services outside the VHA, and so this study 
may underreport women’s acceptance of substance-use treatment services. 
 These studies are important to the current study because they suggest that female 
veterans may have different health-care utilization and patient acceptance compared with 
male veterans. These differences in outpatient service utilization and in treatment 
acceptance provides additional support for the current study’s investigation into whether 
there are gender differences in patient acceptance for HCV treatment.   
Studies of Hepatitis C Screening and Treatment Referrals  
 There have been a number of studies examining patient differences and treatment 
referrals in patients with hepatitis C (Bini, 2005; Dominitz, 2005).  Many of these studies 
were in large cohorts of patients in both veteran and nonveteran populations. These 
studies are important in fostering understanding that the hepatitis C-infected population is 
not homogenous and that there may be differences in this population; however, these 
studies either specifically excluded women due to the small number of women available 
for their study or did not focus on gender in their investigation. Nonetheless, these studies 
are important for a better understanding of potential differences in risks and screening for 
hepatitis C that might challenge the use of universal screening for HCV treatment. These 
screening and treatment differences are exemplified by the original data source of the 
current study.  
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A large U.S. multicenter prospective study of veterans with hepatitis C was 
conducted by Bini et al. (2005), in which all patients were screened for HCV treatment 
candidacy. Demographic, risk factors, such as alcohol use and injection drug use, and 
clinical data were collected at baseline, and a screening for treatment candidacy was 
conducted and recorded. Persons who met treatment criteria were offered treatment, and, 
if accepted, were treated. In persons who did not meet criteria for treatment, reasons for 
ineligibility to HCV treatment were recorded. A convenience sample of 4,084 veterans 
from 24 VA medical centers was enrolled in the study.  
Overall, the study was predominantly male (97.2%); 59.5% reported injection 
drug use and 75.4% reported consuming more than 3 drinks of alcohol per day on a 
regular basis. In this study, only 32.2% were candidates for HCV treatment. The reasons 
for ineligibility of persons for treatment were ongoing or recent substance use (20.2%) 
and active psychiatric disease, including depression and other comorbid diseases 
(17.9%). Multivariate analysis of factors associated with not being a treatment candidate 
showed that persons with preexisting psychiatric disease, including depression, were 
statistically significantly 9.45 (95% CI=6.70-13.32) times less likely to be treatment 
candidates than those without mental-health issues. In the group of persons eligible for 
treatment, there was a high rate of refusal, with 23.8% not accepting treatment. The 
primary reasons for declining therapy included deferring for future treatments (50.3%), 
concerns regarding potential side effects, such as depression (21.6%), and concerns 
regarding their ability to comply with therapy (2.2%).  
There are a number of limitations and strengths of this study. For instance, this 
study population may underreport risk factors and behaviors such as depression and 
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mental health in veterans with HCV because the study represents patients who already 
were referred for screening for HCV treatment, and, therefore, persons who had severe 
mental-health and substance-use issues may not have been referred because they would 
not have been deemed good HCV-treatment candidates. Another limitation is that it did 
not address gender-specific questions pertaining to HCV patient screening and 
acceptance. The strengths of this study were its large sample size and multicenter 
population. This study was well designed and identified the high prevalence of mental 
health and behaviors that might affect negatively a person’s ability to initiate therapy and 
identified self-reported concerns about adherence and concern for management of side 
effects. This well-defined group of veterans with hepatitis C from a broad range of sites 
across the nation provides the foundation of the current study. It is important to further 
examine these data to assess whether there are gender differences in HCV treatment 
screening and treatment acceptance. 
 A second, large non-VA retrospective study by Trooskin et al. (2007) examined 
HCV risks, testing, and referrals in the general patient population in four medical 
facilities in the Philadelphia area. This study of 4,407 patient records (1,818 males and 
2,469 females) from both academic and community-based clinics’ primary study aim was 
to investigate the role of race and ethnicity on patient screening and treatment referrals. 
To examine this aim, the investigators used chi-square tests and logistic regression 
analysis to assess statistical differences between race and ethnicity, at which time they 
also examined gender differences. This study found that males were statistically 
significantly more likely to have a positive risk-factor history when compared with 
females (54 vs. 30%). The positive-risk factors that  men were more likely to have 
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included a history of injection drug use, a history of heavy (3 or more drinks per day) 
alcohol use, and a history of other blood and other bodily fluid exposures. These data 
suggest that there are gender differences for risk factors for HCV.  Another not 
statistically significant finding of the study was that, of the 93 patients who had chronic 
HCV, 71% of European American patients were referred to treatment compared with 
40% of Hispanic Americans and 32% of African Americans. These data suggest that 
there may be screening differences associated with race and ethnicity and that universal 
screening may not be appropriate for the entire HCV population.  
This study had a number of limitations. First, the sample was only from clinics in 
the Philadelphia area, which might mean there are geographic differences that would 
limit generalizability to the general HCV population. Another limitation is that the study 
obtained data only from patient medical records, which might introduce specific 
physician or clinical bias in their reporting of risk factors and referrals. It also did not 
account for the fact that some patients might access their health care at other facilities and 
thus these data would underreport treatment and referrals to other studies. This study did 
have a large population of both men and women and did review chart records consistently 
at each of the four medical centers. Although this study did not focus specifically on 
treatment acceptance and referrals among women, it does suggest differences in risk 
factors and behaviors between men and women and also suggest that other factors (in this 
case race and ethnicity) are associated with differences in treatment acceptance and 
referrals.  
 Results from these HCV studies suggest that there may be patient differences for 
the current HCV screening criterion, such as modifiable factors like substance use and 
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mental health. These studies suggest that there also might be factors associated with 
differences in HCV treatment acceptance among different groups of veterans. These 
studies, however, did not address the issue of whether there were gender differences 
associated with HCV treatment screening and HCV treatment acceptance, which further 
supports the need for the current study.  
Gender Differences in the Natural History of Liver Disease and Treatment Outcomes 
Universal screening for HCV treatment is based on the principle that there are no 
differences in the effects of HCV on liver disease based on gender. Research data, 
however, suggest that there are differences in the progression of liver disease between 
men and women. A study by Poynard et al. (2002) examined fibrosis progression in a 
large cohort of 4,852 patients from patient records in France, Germany, China, and the 
US. In the natural history of liver disease associated with HCV, fibrosis is an 
inflammation of the liver, which, overtime, can lead to cirrhosis or scarring of the liver 
and possibly death. The study investigators used hazard function, log-rank test, and 
proportional regression analysis as described previously. These data suggest liver disease 
progression (fibrosis) in HCV-infected women is different than for HCV-infected men. 
Women have a steeper acceleration in liver disease at age 60 and that fibrosis started 
earlier and progressed faster for advanced liver disease in women. Further analysis 
showed that alcohol use accelerated liver disease in women statistically significantly 
faster than men (20 vs. 35 years). Using exposure modeling, age at HCV infection was a 
statistically significant independent factor for disease progression (relative risk = 11.1 
after 40 years) and, in those who consumed alcohol, HCV-related disease progression 
was associated statistically significantly and independently with age at onset of alcohol 
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use (relative risk = 8.1 after 40 years of age), and gender, with slower progression in 
males (relative risk = .6).  
There are several limitations of this study. Fibrosis progression scores are based 
on a liver biopsy test, both of which are dependent on the skills and expertise of the 
individual pathologist. The dependence of the skills of the pathologist means that there 
may be significant differences in scoring (or interrater reliability) between fibrosis scores 
across sites and countries. The large data set and the high-volume centers involved in the 
study might eradicate some of these potential reliability issues. This study’s data also are 
reliant on medical record for behaviors such as date of infection (and, therefore, date of a 
risky blood-to-blood exposure) and alcohol use, and it may underreport these risky 
behaviors based on patient disclosure to his or her physician. These data, however, 
suggest variability in disease progression as a result of age, gender, and other risk 
behaviors, such as alcohol use. The Poynard study data suggest the need to further 
examine the specific type (or quality) of responses, by gender, to the current HCV 
treatment screening, which is one of the purposes of this study. 
HCV Treatment and its Potential Serious Side Effects  
The standard treatment for HCV is now a combination of pegylated interferon and 
ribavirin. The pegylated interferon is a one-time per week injection, and the ribavirin 
involves a daily dose of pills. This combination of therapy has improved patient 
outcomes substantially since 2003  and, unlike many other infectious diseases such as 
HIV, a large percentage (40 to 90%) of patients who are treated are able to clear the virus 
and essentially be cured (Manns, Wedemeyer, & Cornberg, 2006). Thus, with such a high 
potential benefit or success rate for treating HCV and the high potential costs or 
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consequences with not treating HCV, including liver transplant or even death, one might 
question the necessity of universal or any type of screening for HCV treatment in lieu of 
treating all patients with HCV. Unfortunately, the success of HCV treatment, however, 
does have its costs. Persons undergoing HCV treatment often have side effects that are a 
direct result of the treatment. These include flu-like symptoms, nausea, temporary 
impotence, hair loss, and even mental-health effects including depression or even suicidal 
ideation (Yee, Currie, Darling, & Wright, 2006). As such, the benefits of not treating 
some patients for their HCV may outweigh the potential costs, supporting the current 
universal screening to assess these potential costs or benefits. There are little data, 
however, on the effects of improvements to modifiable, preexisting negative screening 
factors, such as depression, on HCV treatment outcomes, especially in women. These 
data might affect the universal screening by stratifying and qualifying modifiable 
exclusion criterion from changeable criteria, which is a component of the existing study. 
The remainder of this section contains some of the limited studies in this area.  
Approximately 80% of patients with hepatitis C at VA Medical Centers have 
psychiatric diagnoses (El-Serag et al., 2002). As such, depression has been considered an 
exclusion criterion for receiving HCV therapy due to the concern that the treatment itself 
has been shown to cause or exacerbate depressive symptoms. Risk factors for developing 
depression while on HCV therapy include the presence of mood and anxiety symptoms 
prior to antiviral therapy, a history of major depression, being female, higher interferon 
(HCV treatment) dosage, and longer therapy duration (Raison, Demetrashvili, & 
Capuron, 2005). Dollarhide et al. (2007) examined the role that a psychiatric condition 
had on HCV treatment outcomes. This retrospective study of 130 HCV positive veterans 
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reviewed their medical records for baseline psychiatric and substance-use diagnoses for 
all patients started on treatment between the period of 2000 and 2004 at a single VA 
medical center. Chi-square analyses were conducted to examine the association between 
nominal variables and treatment completion. A logistic regression model was developed 
within patients who completed HCV therapy using a backward Wald method with only 
statistically significant variables entered into the model.  
The study group was 96.2% male, with a high prevalence of substance use 
(85.8%) and 52.8% having a comorbid psychiatric disorder and substance-use 
dependence. Forty percent of all veterans in the study had a history of depression, and 
60% were prescribed antidepressants during the course of treatment. After excluding 
persons who were discontinued due to nonresponse, 13% of patients discontinued therapy 
as a result of psychiatric adverse effects. The  logistic regression analysis, however, 
showed that only weight (> 100 kg) was associated with statistically significantly greater 
odds of completed treatment (OR = 2.90, 95% CI=1.07 – 7.91) and history of psychiatric 
or substance-use issues, ethnicity or race, and other comorbid conditions such as cardiac, 
diabetes, and hypertension were not statistically significant and excluded from the model.  
This study has several limitations, including its smaller sample size and its 
homogeneous, predominantly male population from a single VA medical facility. These 
issues might limit the study’s generalizability to the entire VA population; however, the 
study’s utilization of medical, substance use, and psychiatric medical records does 
suggest that at least two of the modifiable factors in the current universal HCV treatment 
screening, substance use and mental health, may not play as great a role in HCV 
treatment adherence and outcomes as initially proposed. The results of this study also 
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suggest that, once again, little data are available to validate whether these results are 
relevant for female veterans. 
A number of other research studies (Bini et al., 2005; Fireman et al., 2005; Knott 
et al., 2006) have investigated some of the modifiable or unchangeable factors that are 
included in the current VA screening criteria, but the lack of number of women included 
in these studies make it difficult to examine whether these factors have an impact on 
women similar to men. For example, the study by Rowan et al. (2005) investigated the 
role that physical and psychosocial factors played in HCV veteran patients’ quality of 
life.   
The Rowan (2005) study utilized validated study instruments including the Short 
Form 36 and Beck Depression Inventory (BDI) as well as other sociodemographic and 
clinical measures, such as cirrhosis, comorbid conditions, and HCV virological data. The 
results of this study showed that depression (according to the BDI) showed the strongest 
statistically significant relationship to health-related quality of life in patients not on HCV 
treatment and being considered for treatment (Pearson Product-Moment Correlation 
Coefficient of -.71). These data suggest also that chronic HCV affects depression and 
mental health in patients prior to therapy, which does support the current use of mental 
health, including depression on the current study’s HCV screening form. The limitation 
of the Rowan study, however, is that it was a small study of only 62 patients, it only 
included 3 women, and, therefore, it may not be generalizable to the entire VA patient 
population. 
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Summary 
 An overview of the increasing number of women veterans in the VA health-care 
system as well as the high prevalence of HCV infection among veterans was provided in 
Chapter I. Further outlined in this chapter is the general issue of whether veterans’ health 
services, which are based on a male-dominated biomedical model, are effective and 
appropriate. Specifically, in this chapter, the need to evaluate gender-neutral screening 
for health services for female veterans HCV is outlined. This historical lack of women 
veterans and lack of clinical evidence suggests that little is known in this area, even 
though there is an increasing prominence of HCV-related health issues and women 
accessing VA health services. 
 Chapter II contained a review of the relevant literature pertaining to the 
independent variable gender and its association with VA health-care and treatment 
services. This chapter provided a review of the limited empirical studies of other health 
services for veterans suggesting that there are gender differences in screening factors for 
other chronic diseases in veterans. This chapter also provided data from other studies 
suggesting gender differences in health-care utilization and in acceptance for other 
treatments such as smoking cessation. A review of the literature also examined studies 
specific to HCV screening and referrals, including some of the 13 screening factors that 
comprise the standardized HCV screening criteria.  Overall, this review of literature 
suggests that there are contradictory data on the role of gender in overall health and 
health-services access, including universal screening, among veterans.  This literature 
review also suggests that there are gender differences in treatment acceptance for other 
diseases; however, there are few empirical VA studies in HCV that would allow the 
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existing research data to be generalizable or applicable to female veterans with HCV. 
Furthermore, the review of the literature provides information  that there exist data in 
other chronic diseases suggesting gender differences in medical conditions, including 
liver-disease progression, risk behaviors, treatment screening, and treatment utilization. 
Even though literature exists for other diseases, there are no empirical studies that 
specifically examined gender differences in veterans being screened for HCV treatment, 
further supporting the need for the current investigation.  
 Chapter III provides a framework of this study’s methodology, including an 
overview of the original study that is the basis of the current study. Chapter IV provides 
the results of this study with respect to the four research questions. Chapter V provides a 
discussion of these data in the context of the limited published data in this area, its 
implications for practice, and for future research. 
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CHAPTER III 
METHODOLOGY 
 The purposes of this study were to evaluate whether there are gender differences 
in veterans’ responses to the screening for hepatitis C virus (HCV) antiviral treatment and 
in those who accept HCV antiviral treatment.  HCV antiviral treatment screening and 
HCV treatment acceptance are two separate decision points for all veterans being 
considered for HCV treatment. Specifically, this study examined the responses to the 13 
exclusion criteria that comprise the Veterans Administration’s (VA) universal screening 
criteria for HCV (Appendix A) not only in the types of responses but also total number of 
yes responses to the exclusion criteria between female and male veterans. In the group of 
veterans who are eligible for and offered treatment, this study investigated whether there 
were gender differences in acceptance of HCV antiviral treatment. This chapter contains 
a section on the methodology for the study. The chapter includes an overview of the 
study’s research design, study population, data collection, and subsequent data analyses. 
Research Design 
This study was a secondary analysis of data from a study by Bini et al. (2005) of 
4,269 veteran patients recruited from the Gastroenterology, Hepatology, and Infectious 
Diseases clinics at 24 geographically diverse Veterans Administration (VA) Medical 
Centers throughout the US between December 1999 and December 2000. The present 
study examined the data from the Bini study by comparing the responses between the 
4,151 male and 118 female respondents to the 13 HCV treatment exclusion criteria as 
well as the proportion of HCV-infected female veterans who were HCV treatment 
candidates according to these 13 screening exclusion criteria (see Appendix A).  
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In order to be considered a treatment candidate for HCV, patients could not have 
a single yes response to any one of the 13 screening exclusion criteria (see Appendix A). 
If a patient responds yes to any one of the 13 screening exclusion criteria, he or she was 
excluded from HCV treatment. The number of persons who did not have a yes response 
to any of the 13 exclusion criteria comprised the number of persons who meet HCV 
treatment eligibility, and it is these results that provided the comparison of the number of 
male and female veterans eligible for HCV treatment. The 13 exclusion criteria 
comprised the 13 dependent variables for this research question (see Table 1). 
This study compared the quantity of responses to all 13 variables between male 
and female veterans screened for HCV treatment (see Table 1). The quantity of responses 
is defined as the number of persons who responded to yes for one, two, three, and up to 
13 potential screening exclusion criteria responses, rather than just a single determination 
of yes or no treatment candidacy based on a single yes response. The quality of responses 
to each variable also was compared by gender, for each of the 13 responses. This was 
done by categorizing screening factors as modifiable (changeable) factors or 
unchangeable factors. The responses to unchangeable factors (which are defined as 
medical laboratory test results, existing medical diseases, or contraindicated other 
treatments that would be difficult or impossible to change for the patient) and modifiable 
factors (which are defined as behaviors, conditions, or factors that potentially can be 
changed by the patient, such as mental health, substance use, and adherence for HCV) 
were examined (see Table 1). The study also was designed to investigate other factors 
(such as alcohol use), socioeconomic differences (such as education level), and 
demographic factors (such as race or ethnicity), if there were gender differences in the 
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quality of responses; however, these analyses were not necessary and were not 
conducted. 
Table 1 
Exclusion Criteria or Dependent Study Variables by Research Question 
 
Research Question (number of variables)  Exclusion Criteria or Variable name  
#1 HCV treatment screening (13)   Unchangeable Factors 
Prior HCV treatment    
       Hypersensitivity to HCV  
       Hemoglobinopathies   
       Advanced liver disease   
       HBsAb positive    
       Preexisting medical condition  
       Evidence of ischemia (cardiac)  
       Concurrent use of other HCV drugs  
       History of organ transplant   
       Modifiable Factors 
       Ongoing substance use  
       Preexisting psychiatric conditions 
       Inability to remain compliant   
       Patient or partner is pregnant   
#2 Other factors associated with gender (6)  Current or recent alcohol use   
       Current or recent injection drug use  
Income level > $10,000   
       Completed high school or more  
       Age > 50 years of age    
       African-American    
#3 HCV treatment acceptance (1)   Treatment acceptance    
#4 Reasons for HCV Treatment   Potential side effects    
Nonacceptance (6)     Ability to comply   
       Contraception issues    
       Concerns over substance abuse  
       Treatment at a later date   
       Other      
 
This study compared the proportion of female and male veterans who were 
considered treatment candidates according to the universal screening exclusion criteria 
and who, when offered, accepted the HCV treatment. This comparison was done by 
comparing the number of yes responses to treatment acceptance by gender. For the 
purposes of this research question, treatment acceptance was the dependent variable. 
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Additionally, in the subset of all male and female veterans with hepatitis C who were 
offered treatment and did not accept treatment, a phi coefficient was used for each of the 
six potential reasons why the patient did not choose treatment. The six potential 
responses to HCV treatment nonacceptance comprise the dependent variables for 
research question number 4. Table 1 provides an overview of the dependent variables for 
each of the study’s four research questions.  
Population 
 
Patients were eligible for the Bini et al. (2005) study if they were a U.S. veteran 
receiving care at one of the 24 participating study sites, were older than 18 years of age, 
had a positive HCV antibody test (Ortho HCV ELISA version 3.0; Ortho-Clinical 
Diagnostics, Inc., Raritan, NJ), and were under consideration for HCV treatment with 
interferon alfa-2b and ribavirin. Patients were excluded from the Bini et al. study if they 
had no presence of HCV virus by polymerase-chain-reaction testing or if they were 
coinfected with HIV. There were 4,201 veterans included in the study, of which 4,084 
(97.2%) were male and 117 (2.8%) were female. The study population was 50.3 years old 
(+ 7.6 years) and racially diverse with 56.9% European American, 29.9% African 
American, 9.2 % Hispanic American (Black or non-Black), and 3.7% Other. Table 2 
provides an overview of the demographics of the study population, stratified by gender. 
The female veterans in the study were statistically significantly younger. Table 3 
provides the results of the independent t tests of age, grouped by gender.  
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Table 2 
Frequencies of Demographic and Socioeconomic Variables of 4,201 Veterans by Gender 
             
Demographic           Females             Males    
Characteristics   Total  f        % Total  f          %   
Age > 50    104 47    46 3,783 1,909  50   
African American   117 33    28 4,068 1,220 30   
Income <10,000/year   116 38    33 4,046 1,578  30  
< High-school education  117 22    19 4,064 2,032    50 
History of incarceration     84 36    43 3,474 2,570    74   
History of drug use      99 43    43 3,677 2,500    68  
Alcohol use in past 12 months 116 36    31 4,035 1,949    48   
 
Table 3 
Means, Standard Deviations, and Independent t-Test Result for Age 
in 3,887 Veterans by Gender 
 
                    t 
Demographic variable  Gender      f  Mean   SD     df 
Age    Female    104  45.63 7.20          -6.40* 
    Male  3,783  50.46 7.61 3,885   
*Statistically significant when overall error rate controlled at .05 level 
 
Table 4 
Chi-square Results Comparing Demographic and Socioeconomic Variables of Female 
Veterans Compared with Male Veterans (N = 4,201) 
 
                Female Male        
Variable        Response   f   % f % Total      χ2 
African American  Yes 33 28 1,220 30 1,253    0.17 
    No 84 82 2,848 70 2,932 
Income <10,000/year  Yes 38 33 1,578 39 1,616    1.67 
    No 77 67 2,468 61 2,545 
< High-school education Yes 22 19 1,951 48 1,973 38.92* 
    No 95 81 2,113 52 2,208 
History of incarceration  Yes 36 43 2,571 68 2,607 40.64* 
    No 48 57    903 32    951 
History of drug use  Yes 43 43 2,500 74 2,543 26.43*  
    No 56 57 1,177 26 1,233 
Alcohol use, past 12 months Yes 36 31 1,493 37 1,529   1.73 
    No 80 69 2,542 63 2.622   
*Statistically significant when overall error rate is controlled at .05 level 
 
Table 4 provides the results of the chi-square tests of the other socioeconomic and 
demographic variables, grouped by gender. In addition to being younger, female veterans 
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were statistically significantly more educated and less likely to have a history of drug use 
or a history of incarceration compared with the male veterans in the study. 
Protection of Human Subjects 
 
For the Bini et al. (2005) study, all persons provided written informed consent to 
participate. All study data were entered on case-report forms and faxed to a central 
location (Therapeias Health Management, Claremont, CA) for review and processing. 
The original study data were cleaned and coded for Excel, Statistical Analysis System 
(SAS), and Statistical Package for the Social Sciences (SPSS), and these data were 
stripped of any patient identifiers prior to data analyses. It was in this form that these data 
were obtained for this study. The Bini et al. study was approved by the local Institutional 
Review Board (IRB) at each of the 24 medical centers. This study did not require IRB 
consent from the University of San Francisco because the IRB determined that it was a 
post-hoc analysis of an existing data set and no additional review was needed. 
Study Instruments 
This study’s two instruments, the HCV treatment screening form containing 13 
exclusion criteria and questions #4  and #5 of the HCV treatment candidacy and decision 
form, were developed and created for a large VA multicenter HCV treatment study in 
1999 known as the VA-HCV-001 study group (Bini et al., 2005). 
The HCV treatment exclusion criteria form was developed based on the VHA’s 
Standardized HCV Treatment Criteria (Veterans Affairs, 2003). The form is comprised of 
13 items. These 13 items were developed utilizing the biomedical model and require a 
yes-or-no response to each item. A person is defined as being excluded from HCV 
treatment if he or she responds yes to just one of the 13 responses. The 13 items include 
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four modifiable factors, ongoing or recent substance use, pregnancy, medical compliance, 
and preexisting psychiatric conditions (including uncontrolled depression). These factors 
are part of the HCV screening because they not only can have a negative impact on 
treatment outcomes or success but also have the potential to cause or exacerbate other 
adverse effects or medical conditions in patients. For example, substance use, similar to 
medical compliance, has been linked with treatment adherence and, therefore, treatment 
success. The HCV treatment is teratogenic, which means that it potentially can cause 
birth defects. Pre-existing medical conditions are screened for because the HCV 
treatment can exacerbate existing mental-health conditions. HCV treatment has been 
associated with depression and suicidal ideations. The screening also identifies nine 
unchangeable factors, such as a history of organ transplantation or having cardiac issues 
that also might put the patient at risk (see Appendix A for further details).  
The HCV treatment candidacy and decision form was codeveloped by the 24 
original VA multicenter study investigators. This form was developed to summarize data 
on whether a veteran who was screened for HCV treatment was considered a candidate 
for treatment; using this form, data also were collected on whether the patient agreed to 
receive treatment or not, as well as seven reasons for not accepting treatment (Appendix 
B, question # 5). The response choices for each of the questions on this form were 
developed by the 24 study investigators. These responses were based on the 
investigators’ opinions of what the most frequent responses to each question would be 
using their clinical experience and available data. The instrument allows for only a single 
response to this question, which means that only a single yes-or-no response could be 
recorded to indicate the primary reason that the patient did not accept HCV treatment. 
 54
For the purposes of this study, 6 of 7 reasons for not accepting treatment were examined 
and analyzed. The seventh reason, which states that patients did not want to be in a study, 
was excluded from the analysis because this was an indicator of study acceptance and 
was not relevant to the analysis of treatment acceptance. Both study instruments were 
designed to be completed by the healthcare provider and were developed in a teleform 
format. This format helped facilitate data collection by allowing each site to scan the 
forms to a centralized data server.   
The HCV treatment screening exclusion-criteria form and the HCV treatment 
candidacy and decision forms were administered by the study investigator, who was the 
treating clinician or the study nurse at each site. There are no validity and reliability data 
available for these forms. Prior to the forms’ use in the Bini et al. (2005) study, the forms 
were piloted at a single site. The single-site pilot including the use of the forms as 
screening tools with 10 veterans with chronic hepatitis C who were being considered for 
HCV treatment to assess responses and length of time for completion of each form. 
Additionally, prior to study enrollment, all study staff met as a group and were trained, as 
a group, on the use of the forms and data collection for the study. This training included 
the review of each question and clarification of types of responses, as well as all study 
protocols and procedures, including patient education and counseling that might result 
from this screening.  
Data Collection 
At the time of the original study enrollment, all patients received comprehensive 
HCV counseling and education, including the risks of HCV transmission, potential 
positive lifestyle changes, the natural history and prognosis of chronic HCV infection, 
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and HCV treatment options. Patients were interviewed by trained research coordinators 
who obtained detailed demographic, clinical, and risk-factor information. Data collected 
on each patient included age, gender, race or ethnicity, era of military service, level of 
education, annual household income, use of alcohol, and risk factors for HCV infection, 
including injection drug use, blood transfusions prior to 1990, combat-related injuries, 
blood contact during combat, needlestick injuries, acupuncture, tattoo, body piercing, 
incarceration for more than 48 hours, intranasal cocaine use, and sexual history. 
All patients were evaluated for HCV therapy by a trained clinical research 
coordinator or the study clinician using the standardized 13 exclusion criteria form (see 
Appendix A), which was based on the current Veterans Health Administration’s (VHA) 
HCV Treatment Recommendations. This standardized screening form was used at all 24 
participating medical centers. In addition to determining treatment candidacy according 
to the 13 standardized exclusion criteria, the study collected data on those veteran 
patients who were considered eligible for antiviral therapy by the treating clinician. The 
treating clinician at each medical center was a Gastroenterologist, Hepatologist, or 
Infectious Diseases specialist who was experienced in the management of patients with 
chronic HCV infection. 
All of the patients who did not meet any of the 13 exclusion criteria for HCV 
treatment were considered eligible for, and offered, HCV treatment by the trained clinical 
research coordinator or study clinician. The patient responses to whether he or she 
accepted treatment was recorded on the treatment candidacy and decision form (see 
Appendix B), as well as the reasons why they refused therapy (see Appendix B).  
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Research Questions 
The following research questions were investigated: 
1. To what extent are there gender differences in the quantity and type (whether 
they are modifiable or not) of responses to standardized patient screening in veterans with 
chronic HCV?  
2. If there are gender differences in the type of responses to standardized patient 
screening, is this difference associated with risk factors, such as alcohol use, 
socioeconomic differences, such as level of education, and demographic factors, such as 
race or ethnicity, of veterans with chronic HCV? 
3. To what extent are there gender differences in treatment acceptance in veterans 
who are offered HCV antiviral treatment? 
 4. For those who do not accept HCV treatment, to what extent do the reasons for 
nonacceptance differ by gender? 
Data Analysis 
To address the quality of responses in research question one, a phi coefficient was 
used for each of the 13 screening criteria. All responses were considered statistically 
significant when the overall error rate is controlled at a .05 level using the Bonferroni 
correction. To further address the quality of responses in research question number one, a 
subgroup analysis was performed in those veterans who had at least one yes response to 
any of the 13 screening criteria. This subgroup of veterans who met at least one exclusion 
criteria were categorized into a group with only changeable exclusion criteria and a group 
with at least one unchangeable criteria. A chi-square analysis was performed where 
gender was one variable and the other variable was whether they had only changeable 
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exclusion screening criteria or not. To further examine the quality of the screening 
exclusion criteria responses by gender, another chi-square analysis was performed 
comparing the proportion of female veterans who did not meet any screening exclusion 
criteria with male veterans. Finally, to address the quantity of responses in research 
question one, the number of yes responses to the 13 criteria was compared for men and 
women using an independent-samples t test with a significance level of .05.  
To address research question two regarding differences in risk factors (such as 
alcohol use), socioeconomic differences (such as education level), and demographic 
factors (such as race or ethnicity), a log-linear analysis was designed to be performed on 
the risk factors, gender, and exclusion criteria only if there were gender differences in the 
quality and quantity of responses to standardized HCV treatment screening. 
To address research question three regarding differences in patient acceptance, a 
chi-square analyses was performed where gender is one variable and the other variable 
was the response to the question whether the patient agreed to receive treatment (see 
Table 1 or Appendix B, #4). 
To address research question four, a phi coefficient was used for each of the six 
potential reasons why the patient did not choose treatment and the other variable was 
gender.  The overall error rate was controlled at the .05 level using the Bonferroni 
correction for the coefficients.   
Summary 
 In this chapter, an overview of the population, the data-collection instruments and 
data analyses for the study were provided. This information highlights the fact that it was 
a large study population, with a large amount of data collected to examine potential 
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differences in HCV treatment screening and HCV treatment acceptance. Chapter IV 
contains the results of this study with respect to the four research questions. Chapter V 
has the discussion of these data in the context of the limited published data in this area, its 
implications for practice, and for future research. 
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CHAPTER IV 
RESULTS 
The purposes of this study were to examine gender differences in veterans’ 
responses to screening for HCV antiviral treatment and gender differences in the 
acceptance of HCV antiviral treatment. Chapter IV provides the results of this study by 
each research question. 
Research Question 1 
To what extent are there gender differences in the quantity and type (whether they 
are modifiable or not) of responses to standardized patient screening in veterans with 
chronic HCV?  
 The 13 universal screening criteria were analyzed using a phi coefficient to 
investigate whether there were differences in the type of responses for female and male 
veterans. The results of the phi coefficient for all 13 universal criteria were all close to 
zero (see Table 5 for more details). Overall, only 4 of the 13 universal screening criteria 
had more than 5% yes responses for either male or female veterans, preexisting medical 
conditions, evidence of advanced liver disease, substance use, and psychiatric issues. For 
these criteria, female and male veterans had psychiatric conditions (18.8% and 18.0%), 
preexisting medical conditions (16.2% and 19.3%), and evidence of advanced liver 
disease (3.4% and 6.0%), but these differences were not statistically significant. The 
proportion of female veterans who were excluded from HCV treatment due to substance 
use was 12.8% compared with 20.3% for male veterans; this difference was not 
statistically significant when the overall error rate was controlled at a .05 level using the 
Bonferroni correction. Table 5 shows further details of this analysis. 
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Table 5 
Phi Coefficient Results Comparing the Yes and No Responses to the 13 Standardized 
Patient Screening Exclusion Criteria in Veterans 
 
                             Gender  
Screening       Female Male     
Criteria   Total Response f % f %    Phi 
Prior HCV treatment  4,133 No  115    98.3 4,018   98.6 -.004 
     Yes      2     1.7      59    1.4   
Hypersensitivity  4,193 No  117    100.0 4,076 100.0  .003  
     Yes      0       0.0        1     0.0   
Anemia   4,120 No  116   99.1 4,004   98.5  .008  
     Yes      1       0.9      59   1.5  
Liver disease   3,927 No  113  96.6 3,814   94.0  .018  
     Yes      4       3.4    244   6.0  
Hepatitis B Positive  3,974 No  117    100.0 3,857  98.3  .022  
     Yes      0        0.0      66     1.7  
Preexisting conditions  3,364 No    98      83.8 3,266   80.7  .013  
     Yes    19   16.2    781   19.3  
Unapproved treatment 4,159 No  116   99.1 4,043   99.4 -.005  
     Yes      1        0.9      25     0.6  
Ischemia   3,996 No  115   98.3 3,881   95.9  .020  
     Yes      2       1.7    167     4.1  
Organ transplant  4,146 No  115      98.3 4,031    99.0 -.011  
     Yes      2       1.7      41      1.0   
Substance Use   3,338 No  102      87.2 3,236    79.7  .031 
     Yes    15      12.8    824    20.3 
Psychiatric conditions  3,420 No    95      81.2 3,325    82.0 -.003 
     Yes    22      18.8    730    18.0  
Inability to comply  4,017 No  114      97.4 3,903    95.9  .013 
     Yes      3       2.6    167      4.1 
Pregnancy   4,180 No  117    100.0 4,063    99.9  .006 
     Yes      0        0.0        5      0.1   
 
An examination of the quantity of yes responses to any of the 13 screening criteria 
showed that 2,106 (50.1%) of both male and female veterans had at least one yes 
response to one of the 13 HCV treatment screening exclusion criteria, and, therefore, 
were ineligible for HCV treatment.  The number of yes responses to the 13 screening 
exclusion criteria was compared for female and male veterans using an independent-
sample t test with a significance level of .05. Overall, there was no statistically significant 
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difference in the mean number of exclusion criteria between female and male veterans. 
Table 6 shows the results of this analysis. 
Table 6 
Means, Standard Deviations, and t-Test Result Comparing Female Veterans with Male 
Veterans on the number of the 13 HCV Treatment Screening Exclusion Criteria (n= 
2,106) 
 
    Standard          t 
Gender  Mean Deviation df = 2,105 
Females  1.48  0.71       .53  
Males   1.57 0.74     
 
Veterans are excluded from HCV treatment if they have a yes response to any one 
of the 13 exclusion criteria. To further examine the quantity of the screening exclusion 
criteria responses by gender, a chi-square test was performed comparing the proportion of 
female veterans who did not meet any screening exclusion criteria with male veterans.  
Female veterans were significantly less likely to have one or more exclusion criteria 
when compared with male veterans (41.0% vs. 50.4%). This means that more female 
veterans were HCV treatment candidates (having no exclusion criteria) when compared 
with male veterans (see Table 7 for more details).  
Table 7 
Results of Chi-square Test Comparing the Proportion of Female Veterans Who Met 
Screening Exclusion Criteria With Male Veterans (N = 4,201) 
 
            Female  Male  
Variable    f %      f %  Total    χ2 
No Exclusion Criteria   69  59.0  2,026  49.6 2,095 3.99* 
One or more Exclusion Criteria 48  41.0  2,058  50.4 2,106 
*Statistically significant at the .05 level. 
 
 To further assess the type of the responses of exclusion criteria, a subgroup 
analysis of those 2,106 veterans who had at least one yes response to any of the 13 
exclusion criteria was further analyzed based on those who had modifiable criteria. There 
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were no significant differences between the proportion of female and male veterans who 
had at least one modifiable (potentially changeable) criteria (47.9% vs. 44.9%). Table 8 
shows the results of this analysis.   
Table 8 
Results of Chi-square Test Comparing the Proportion of Veterans Who Had at Least One 
Exclusion Criteria That Was Only Modifiable Exclusion Criteria With Those Who Only 
Had Unchangeable Criteria by Gender (n = 2,106) 
 
       Female       Male    
Exclusion Criteria  f %     f  % Total   χ2 
Only Modifiable Criteria 23  47.9    923 44.9    946   .66 
Nonmodifiable Criteria  25 52.1 1,135 55.1  1,160 
 
Research Question 2 
If there are gender differences in the type of responses to standardized patient 
screening, to what extent are these differences associated with risk factors, such as 
alcohol use, socioeconomic differences, such as level of education, and demographic 
factors, such as race or ethnicity, of veterans with chronic HCV? 
This data analysis was not performed because there were no statistically 
significant differences in the type of responses to standardized patient screening criteria  
Research Question 3 
To what extent are there gender differences in treatment acceptance in veterans 
who are offered HCV antiviral treatment? 
In this study, 2,095 veterans did not have any exclusion criteria; 2,026 men and 
69 women were eligible for HCV treatment. There were 39 veterans excluded from the 
treatment acceptance phase of the study because of their nonconsent to participate. This 
meant that 2,056 (98.1%) of all veterans without any exclusion criteria were included in 
this analysis.  
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Overall, 931 (45.3%) veterans did not accept HCV treatment. There were no 
statistically significantly differences in the number of female veterans who accepted 
HCV treatment compared with male veterans (50.0% vs. 54.9%). Table 9 shows the 
details of this analysis. 
Table 9 
Chi-square Results Comparing the Proportion of Female Veterans Who Were Offered 
HCV Treatment But Did Not Accept Compared With Male Veterans (n = 2,056) 
 
         Female         Male  
Variable    f   %      f  %   Total   χ2  
Did not accept HCV Treatment 33  50.0     898   45.1    931 .61  
Accepted HCV Treatment  33  50.0  1,092  54.9 1,125 
 
Research Question 4 
 For those who do not accept HCV treatment, to what extent do the reasons for 
nonacceptance differ by gender? 
There were 931 persons who did not accept treatment. Of these, 62.2% provided a 
reason why they did not choose to accept treatment. The primary reason for not accepting 
treatment for both female and male veterans was wanting to defer treatment (57.1% vs. 
59.0%); there was no statistically significant difference in this response. The second most 
common reason for not accepting HCV treatment was the concern over HCV treatment 
side effects, (23.8% of all female veterans compared with 10.6% male veterans), but the 
difference in the concern over HCV treatment side effects was not statistically 
significant. The results of this analysis are provided in detail in Table 10. 
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Table 10 
Phi Coefficient Results Comparing the Reasons for HCV Treatment Nonacceptance  
by Gender (n = 579) 
 
          Gender  
Reason for HCV Tx     Female                  Male     
Nonacceptance Response f  %     f %  Phi 
Side effects   No  16   76.2  499 89.4  -.02  
   Yes    5   23.8      59   10.6   
Inability to comply No  20   95.2  522   93.5   .01  
   Yes    1       4.8      36       6.5   
Pregnancy  No  21      100.0  557   99.8   .85 
   Yes    0       0.0          1       0.2  
Substance Use  No  21      100.0  553   99.1   .02 
   Yes    0       0.0          5        0.9  
Treatment Later No    9 42.9  229   41.0   .01  
   Yes  12 57.1  329   59.0  
Other   No  18 83.8  492   88.2  -.01 
   Yes    3 16.2    66   11.8  
 
Summary 
 In this chapter, the results of the data analyses for the study’s four research 
questions were provided. These data highlight the fact that female veterans were 
statistically significantly more likely to be considered candidates for HCV treatment than 
male veterans. These analyses also suggest that none of the individual responses to the 13 
screening criteria for HCV treatment differed statistically between female and male 
veterans. There also were no statistically significant differences in the quality of 
responses when comparing female veterans with only modifiable exclusion criteria with 
male veterans with only modifiable criteria. This chapter also provided results that 
suggested that there were no gender differences in the acceptance of HCV treatment. In 
terms of the reasons for nonacceptance, there were no statistically significant differences 
in the six reasons for nonacceptance either. Chapter V provides a discussion of these data 
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in the context of the limited published data in this area, its implications for practice, and 
for future research. 
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CHAPTER V 
DISCUSSION, CONCLUSIONS, AND IMPLICATIONS 
The purposes of this study were to evaluate whether there were gender differences 
in veterans’ responses to the screening for Hepatitis C Virus (HCV) antiviral treatment 
and gender differences in those who accept HCV antiviral treatment. HCV antiviral 
treatment screening and HCV treatment acceptance are two separate decision points in 
the treatment process for all veterans being considered for HCV treatment. This study 
then would provide additional data to evaluate the efficacy of the Veterans 
Administration (VA) current utilization of its universal, gender neutral screening for 
HCV treatment. This chapter provides a discussion of this study’s results, as well as any 
conclusions and implications these may have for current practice and future research. 
In chapter IV, the study data highlighted the fact that female veterans were 
statistically significantly more likely to be considered candidates for HCV treatment than 
male veterans. Other than the gender difference in the quantity of female veterans who 
were considered HCV treatment candidates, there were no statistically significant gender 
differences in the quality of responses when comparing female veterans with only 
modifiable exclusion criteria with male veterans with only modifiable criteria or in 
acceptance of HCV treatment. 
Limitations 
 
There are several limitations of this study. First, this study’s findings address a 
veteran population and may not be generalizable to a nonveteran population. Second, 
although the process of patient screening and eligibility utilized a standardized screening 
form, the process of patient treatment acceptance within the study did not follow a similar 
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standardized protocol, which might introduce providers’ bias in their approach to 
educating and offering HCV treatment. In other words, the way that a provider counsels 
and offers treatment to a patient may have differed between sites. This provider bias 
could potential skew the patient treatment acceptance responses, but the large sample size 
and multiple sites could reduce any individual site-specific responses to this issue. 
Third, known factors not collected in the original study may have affected the 
patient’s decision to accept HCV treatment, which include a patient who is moving or in 
transition from one city or region to another, or it might include the patient’s HCV 
genotype (genotype 1 is more difficult to treat than genotypes 2, 3, or 4). Fourth, patients 
who participated in this study may have non-VA medical insurance (through their 
employment or a spouse) and had the opportunity to receive medical care and support for 
HCV outside of the VHA, which might have affected their HCV treatment acceptance 
decision within the VA. This is not a major limitation, however, because veterans do 
have access to comprehensive medical coverage within the VA.  
A fifth limitation to this study is the large attrition rate of responses for veterans 
who did not accept HCV treatment. The lower number of responses recorded for veterans 
who did not accept treatment was probably the result of an oversight of the original 
study’s protocols, which did not require study staff to obtain a response to treatment 
accceptance. Of the 931 veterans who did not accept treatment, only 62% provided a 
reason why they did not accept treatment, which might skew or bias the aggregate results; 
however, the number of male and female nonrespondents was not different, and so it 
should not be problematic for the examination of differences by gender. A sixth potential 
limitation is the construct validity and the discriminant ability of the VA’s 13 Screening 
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Exclusion Criteria. In reviewing the responses or lack of responses to many of the 13 
criteria, there may be limitations to the screening ability of the current form, and it also 
limits the statistical power of this study to examine differences between female and male 
veterans with HCV. In nonveterans studies, there is a potential for participants to 
underreport their risky or undesirable behaviors; however, in a veteran population, where 
there is a singular medical record system that includes all of a patient’s mental health, 
substance use, prescription, and related behaviors and where there are no negative 
repercussions or loss of services due to reporting of undesirable behaviors underreporting 
would be minimized. 
Finally, although this is a very large, multicentered data set and a larger number 
of women veterans with HCV than previously examined, there are still a disproportionate 
number of men to women in the data set, which might affect the statistical power of some 
of the statistical analyses such as the examination of the subset of veterans who did not 
accept treatment.  
Discussion 
The prevalence of HCV in the U.S. veteran population is almost three times what 
it is in the general US population (Dominitz et al., 2005). It is also the leading cause of 
liver transplantation and liver cancer in the US (Armstrong et al., 2006). At the same time 
that this high prevalence of HCV and high morbidity and mortality is occurring, the 
gender composition of veterans is changing, with the number of female veterans 
accessing VA healthcare services expected to double by 2010 (Meehan, 2006). The high 
prevalence of HCV, its health toll, and the changing gender composition of VA 
population raise the issue of whether the existing screening is, indeed, appropriate for 
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both male and female veterans. An examination of HCV screening and treatment 
acceptance is especially important to assess because the universal HCV screening form 
was based on a biomedical model that assesses the symptom regardless of gender, race, 
ethnicity, and social circumstance. The biomedical model also is built upon evidence-
based medicine that has been historically male-oriented (Alonso, 2004).  
This study investigated the issue of whether there were gender differences in 
screening and treatment acceptance in veterans with HCV, and, by this examination, any 
potential gender biases in the current universal screening. These data suggest that the 
universal, gender-neutral approach to patient screening appears to be effective for both 
male and female veterans and, therefore, unbiased based on gender. These study data also 
highlight the need for further study of the construct and discriminant validity of the 
screening tool itself. Although there were no statistically significant gender biases in 
HCV screening, these data suggest that providing different patient counseling, education, 
and referrals based upon the current set of universal responses may be beneficial. This 
issue will be further delineated. 
In this large multicentered national study of 4,201 male and female veterans with 
chronic hepatitis C, there was a low prevalence of female veterans (117), which is similar 
to other studies in the VA (Dominitz et al. 2005; Yano et al., 2006). An analysis of this 
study’s population showed that there were demographic and socioeconomic differences 
between female and male veterans. In this study, females were statistically significantly 
younger, more likely to have completed high school, and less like likely to have been 
incarcerated or to have a history of injection drug use. The younger age of female 
veterans, as well as female veterans’ higher level of education and lower risk factors 
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relative to male veterans is similar to the population differences identified by a number of 
other large VA studies by Frayne et al. (2007) and Stecker, Han, Curran, and Booth 
(2007). These socioeconomic and demographic gender differences are similar to a non-
VA study of patients with chronic hepatitis C by Trooskin et al. (2007). 
The first research question was designed to examine gender differences in the 
quantity and type of response to universal screening criteria for chronic hepatitis C, and 
results of this analysis highlighted the fact that only 49.9% of both male and female 
veterans with chronic hepatitis C did not have any of the 13 exclusion criteria and, 
therefore, were eligible for HCV treatment.  A further examination of male and female 
veterans’ responses to the exclusion criteria did show a statistically significant difference 
in the number of female veterans who were eligible for HCV treatment when compared 
with male veterans. These data suggest that 41.0% of female veterans compared with 
50.4% of male veterans were excluded from HCV treatment. 
This study’s examination of whether there were gender differences in the type of 
response to each of the 13 exclusion criteria suggested that there were no statistically 
significant differences between male and female veterans on any of the 13 exclusion 
criteria. Although not statistically significant, however, 20.3% of all male veterans 
compared with 12.8% of female veterans reported substance use. This higher substance 
use among male veterans also was similar to findings by Stecker et al. (2007). Both 
female and male veterans had a high number of positive responses to substance use 
(12.8% vs. 20.3%), psychiatric conditions (18.8% vs. 18.0%), and preexisting medical 
conditions (16.2% vs. 19.3%). The high percentages  of veterans with these health 
conditions are confirmed by other veterans’ studies such as the Lehman and Cheung 
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(2002) study, which reported 44.2% prevalence of depression and 26.7% prevalence of 
substance use in veterans with hepatitis C, and the Fireman et al. (2005) study that  
reported 35% prevalence of depression and 21% alcohol issues, respectively. 
To further examine the type of response to the 13 exclusion criteria, the subgroup 
of 2,106 veterans who responded positively to at least one of the 13 exclusion criteria was 
stratified by those who had only modifiable or changeable conditions versus those who 
had at least one nonmodifiable criterion. This subgroup qualification is a potentially 
important distinction to make because if a veteran had at least one of nine nonmodifiable 
criteria, he or she would never be a candidate for HCV treatment regardless of any health 
improvements or behavioral modifications. In essence, they will never be eligible for 
HCV treatment given the current screening exclusion criteria. Those veterans who had 
only modifiable criteria, however, are patients who may be able make changes and, 
therefore, change their HCV screening status. This categorization is of great potential 
importance, because if there were, indeed, gender differences between the groups with 
unchangeable criteria and those with only modifiable or changeable criteria, it might 
suggest the need for different management and followup strategies between genders. 
These study data show that there were no differences between female and male veterans 
(47.9% vs. 44.9%) with only modifiable criteria. These data suggest that almost half of 
all veterans, both female and male, with potentially modifiable conditions were excluded 
from HCV treatment.  
Although there were no differences between male and female veterans, almost 
half (44.9%) of all veterans reported having only modifiable or changeable exclusion 
factor. These data suggest that a stratified approach to patient education, referrals, and 
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management should be in place to increase the opportunities for changeable exclusion 
criteria to be eliminated and thus to increase the number of female and male veterans 
eligible for HCV treatment. For example, a veteran who is excluded from HCV treatment 
as a result of his or her substance use could be referred and followed up with substance 
use counseling and later would be a candidate for HCV treatment.  
Another indirect result of the examination of the type of response to the 13 
screening exclusion criteria was the low prevalence of yes responses to the majority of 
these 13 criteria. For example, only three of the 13 responses had more than 5% positive 
responses for both male and female veterans. This finding suggests the need to further 
investigate the validity and reliability of the HCV treatment screening criteria for both 
male and female veterans. The HCV treatment screening form appeared to be fast and 
easy to complete, so feasibility may not be the issue, but perhaps the discriminant ability 
of the form should be further examined with so few responses to many of the 13 criteria.   
The final research questions (questions 3 and 4) addressed whether there were 
gender differences in treatment acceptance in veterans who were offered HCV antiviral 
treatment. In this subanalysis, 45.3% (931) of those who were eligible for HCV treatment 
did not accept treatment. This result is surprisingly low when one considers these 
respondents already had participated in a number of procedures to get to the point of an 
HCV treatment decision, including agreeing to be screened and the full screening criteria, 
which includes both biomedical (laboratory) and nonbiomedical processes. Given the 
context of this process, this low percentage of HCV treatment acceptance in this study 
population even may be higher than a nonstudy population. Regardless, these results 
highlight the need to further examine patient education and counseling of both male and 
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female veterans who are eligible for treatment but do not accept HCV treatment. 
Although HCV antiviral treatment is not 100% effective, it is effective in 30 to 90% of all 
persons (Yee, Currie, Darling, & Wright, 2006); on this basis, treatment acceptance 
should be higher for such a high potential cure rate. There were no statistically significant 
gender differences in HCV treatment acceptance between female and male veterans. This 
result did not support the findings of the Sherman, Fu, Joseph, Lanto, and Yano (2007) 
study that concluded that male veterans more likely to access outpatient treatment 
services for smoking cessation or the Stecker et al. (2007) study where male veterans 
were more likely to access substance use treatment services compared with women. This 
study’s data did not support the Frayne et al. (2006) study, finding that female veterans 
were more likely to access outpatient services compared with male veterans. 
In this study’s examination of whether there were gender differences in the 
quality of responses to nonacceptance of HCV treatment, the most common responses for 
nonacceptance in both female and male veterans were concern of side effects and 
deferring treatment until a later date. The concern over side effects highlights the need for 
additional patient education and discussion with the veteran patient to insure that they are 
aware of the potential prevalence of side effects and that they are better able to make an 
informed decision about HCV treatment. This is important given the ability to manage 
most of the side effects that patients might encounter and the efficacy of the HCV 
treatment (Yee et al., 2006). Similarly, it is important to counsel and discuss why a 
veteran is deferring treatment until a later date. This may relate to a patient’s overall 
health or to his or her decision to wait for new and evolving therapies. Regardless, 
deferring treatment should be discussed further with the patient to insure that the veteran 
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patient is making an informed decision. Although there were no statistically significant 
gender differences in responses to not accepting HCV treatment, there did appear to be a 
higher percentage of female veterans not accepting treatment compared with male 
veterans (23.8% vs. 10.6%).  
Implications for Practice 
 There were socioeconomic and demographic differences in female and male 
veterans with HCV. These data may suggest the need to provide different patient 
education and counseling services (e.g., brochures or patient videos for different reading 
levels) to male and female veterans with HCV given that females have a higher level of 
education than male veterans. These data also revealed that female veterans are less likely 
to have had a history of drug use compared with male veterans. In planning for 
appropriate referrals and other linkages to care, it may be beneficial to have more 
referrals and residential treatment options available for male veterans compared with 
female veterans.  
 Another implication of these data for practice is that female veterans were more 
likely to meet the criteria for HCV treatment than male veterans. The higher treatment 
eligibility of female veterans should be disseminated during the training and orientation 
of VA providers throughout health departments and outpatient clinics that are providing 
care for female veterans with HCV. This training would direct providers to refer and 
counsel female veterans with HCV to be screened for HCV treatment.  
Although only half of all veterans were excluded from treatment, this study’s 
results suggest that almost half of both female and male veterans had potentially 
modifiable factors and, therefore, should be the target of health education, counseling, 
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and appropriate referrals (such as substance use counseling and treatment) to improve 
both female and male veterans’ abilities to be eligible for HCV treatment in the future. 
The data suggest that there is a high prevalence of substance use and psychiatric 
conditions (12.8 to 20.3%) excluding both female and male veterans from HCV 
treatment. A multidisciplinary team that included mental-health workers and substance-
use counselors who were integrated into the current liver clinic setting where HCV 
screening occurs would allow for immediate and direct referrals and linkages to these 
necessary psychiatric and substance use resources.  Another potential opportunity is to 
integrate substance-use and mental-health education into the existing HCV screening 
brochures that are available to veterans.  
 Another very important implication for practice is the large number of both 
female and male veterans who were eligible for treatment and did not accept treatment. In 
particular, the majority of veterans who did not accept treatment wished to defer 
treatment or were concerned about the HCV treatment’s side effects. Given the 
opportunity to cure chronic HCV with a short-term (6 months to a year) treatment, it is 
important that HCV providers are further educated on the topic of HCV side effects, as 
well as the appropriate management of any potential side effects and potential strategies 
to improving patient-centered approaches to addressing concerns about side effects for 
veterans with HCV.  
This HCV side-effect education could be implemented through the VA’s existing 
biweekly national teleconference calls with providers, as well as the VA’s Hepatitis C 
Resource Center program by adding side-effect education, patient counseling, and patient 
communication to its existing training programs. This training could include the addition 
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of this side-effect and patient-sensitivity training on this topic to the currently available 
live programs, as well as online for remote HCV providers, and print materials for those 
who prefer this educational format. HCV provider education on this topic would enhance 
his or her ability to better educate, counsel, and discuss the concerns about side effects 
for veterans with HCV and potentially increase the number of veterans who have an 
opportunity to be cured of their chronic HCV disease.  
Finally, although not statistically significant, female veterans did appear to have 
more concerns with HCV treatment side effects, so there may be a need to provide 
additional clinical visit time allotted for female veterans to allow for further education 
and counseling to address the concerns about side effects. Another potential opportunity 
would be to provide gender-specific group-education classes about HCV. This class 
could better address side-effect concerns in a safe, nonthreatening group environment. 
Group education classes have been effective in the VA for substance use and mental-
health group counseling for female veterans and could be modeled for female veterans 
with HCV. 
Implications for Future Research 
The results of this study suggest a number of areas for future research. One would 
be an examination of the construct validity and discriminant ability of the VA’s current 
HCV Screening Form.  For example, further studies are required to assess whether there 
is collinearity within the screening criteria and whether this form based upon the 
biomedical reductionist model actually is screening out the appropriate persons for HCV 
treatment. A study could be conducted on the existing study data to assess those veterans 
with successful treatment outcomes with those who were not successful to evaluate the 
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factors associated with treatment failure. These factors might help identify appropriate 
screening factors for this patient population. Another correlational study of the 13 
exclusion criteria responses should be conducted to investigate if some of these data are 
addressed by another criterion. For example, if 90% of the persons who responded yes to 
substance use also responded yes to having a psychiatric condition, it might suggest that 
only one of these exclusion criteria are necessary for patient screening. As well, a 
qualitative study of the 13 criterion should be undertaken to address and examine the 
prevalence of responses to some of the screening questions. In a large study population of 
over 4,000 patients, 6 of the 13 criteria had fewer than 2% positive responses. A panel or 
focus group of HCV treatment experts could be convened to examine the 13 criteria and 
their benefits of inclusion and risks of exclusion on the screening form. This panel or 
focus group discussion could further examine the positive predictive values and negative 
predictive values of each of the current 13 screening criteria. For example, the benefit of 
finding one patient with hypersensitivity to the HCV medication might outweigh the time 
and burden of screening 4,000 patients for this criterion.  
Future research study would be to examine whether the socioeconomic and 
demographic differences of female and male veterans with HCV is related to their entry 
into the VA’s health system or creates any barriers to accessing healthcare. For example, 
if male veterans have higher risk factors and are more likely to be incarcerated, are they 
more or less likely to be able to access VA healthcare than their female counterparts? The 
results of this study might have major implications for outreach services for patients with 
HCV. 
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Other future research studies could include the implementation and evaluation of 
a number of different patient education or counseling strategies at the screening stage and 
then at the treatment acceptance stage to learn which were the more effective at 
increasing the number of veterans who might be eligible for HCV treatment and in 
increasing the number of veterans who were willing to accept HCV treatment. 
Conclusions 
The purposes of this study were to evaluate whether there were gender differences 
in veterans’ responses to the screening for HCV antiviral treatment and gender 
differences in those who accept HCV antiviral treatment. HCV antiviral treatment 
screening and HCV treatment acceptance are two separate decision points in the 
treatment process for all veterans being considered for HCV treatment. These study data 
suggest that there are gender differences in the population of female and male veterans in 
which females were younger, more educated, and had fewer risk factors.  
These study data suggest that there may be gender differences in the quality of 
responses to HCV treatment screening. Female veterans are more likely to be eligible for 
HCV treatment than male veterans, because they are more likely to have no exclusion 
criteria compared with male veterans. 
This analysis highlighted the fact that half of all veterans, regardless of gender, 
were not eligible for HCV treatment. It also appears that half of these veterans, both male 
and female, had potentially modifiable or changeable exclusion criteria that would 
indicate that there may be a need for different categorization or use of the existing HCV 
Screening Exclusion Criteria form: not on the basis of gender but on the basis of whether 
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an HCV patient has potentially modifiable criteria or unchangeable criteria for further 
referrals, counseling, and education. 
This study did not find any gender differences in the quantity of responses for 
HCV treatment acceptance but that the rate of treatment acceptance, across genders was 
extremely low, with only half of those who met the criteria for HCV treatment accepting 
it. This is a potential source for additional patient education, counseling, and subsequent 
intervention to increase the number of veterans (both female and male) who accept 
treatment and potentially are cured of their HCV. Finally, although there does appear to 
be gender differences in the reasons for nonacceptance, with female veterans more 
concerned about side effects than male veterans, these data suggest that further 
intervention and counseling of all patients who do not accept HCV treatment out of 
concern for side effects is warranted. 
The high proportion of all veterans with HCV, as well as this study’s 
identification of the low proportion of veterans who are eligible for HCV treatment, 
suggests the need to further evaluate the efficacy of the VA’s current HCV screening 
criteria. There are two distinct areas to be considered. One is the need to categorize 
responses to the current screening criteria into only modifiable or changeable criteria. 
This categorization would help facilitate patient education, intervention, and treatment for 
those patients who might be eligible for HCV treatment in the future if they address these 
modifiable exclusion criteria. The second component is the need to evaluate the actual 
screening criteria itself. In this large study of veterans with HCV, it is unclear whether 
the current form has the construct validity and discriminant ability to insure that all 
veterans, regardless of gender, are being screened appropriately to insure that the greatest 
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number of veterans who would benefit from HCV treatment are eligible for HCV 
treatment, with the least amount of risk.  
Finally, the universal, gender-neutral approach to patient screening appears to be 
as effective with both male and female veterans. The need to provide different patient 
counseling and education, however, based upon this set of universal responses, may be 
beneficial. For example, the proportion of veterans who do not accept HCV treatment 
because of fear of side effects may receive different counseling than those who wish to 
defer treatment. This targeted strategy may improve the number of veterans (male or 
female) who are eligible for and accept treatment and ultimately increase the numbers of 
veterans who clear the HCV virus and improve their overall health, by reducing or 
eliminating the complications of HCV such as cirrhosis, hepatocellular carcinoma, end-
stage liver disease, and even death.  
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